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ABSTRACT
p53 modulates a number of cellular responses to genotoxic stress including cell cycle arrest 
and apoptosis. Loss of p53 function either by mutation or otherwise may alter the 
sensitivity of cells to DNA damage. Introduction of a dominant negative p53 mutant 
(codon 143, Val to Ala) has been shown to confer dsplatin resistance in the 
chemosensitive human ovarian A2780 carcinoma cell line. Induced resistance of A2780 
cells to cisplatin was used as the selection strategy to isolate genetic suppressor elements 
(GSEs) from retroviral libraries expressing random fragments of human or murine TP53 
cDNA (Chapter 4). Six GSEs were identified, encoding either dominant negative mutant 
peptides or antisense RNA molecules which corresponded to various regions within the 
TP53 gene. Both types of GSE induced cisplatin resistance when introduced individually 
into A2780 cells.
Expression of antisense GSEs led to decreased intracellular levels of p53 protein. 
One sense GSE induced loss of p53-mediated activities such as DNA damage induced G1 
arrest and apoptosis. A synthetic peptide, representing the predicted amino acid sequence 
of this GSE, conferred resistance to cisplatin when introduced into A2780 cells and 
inhibited the sequence specific DNA binding activity of p53 protein in vitro. Overall, these 
results directly indicate that inactivation of p53 function confers cisplatin resistance in these 
human ovarian tumour cells. We have identified short structural domains of p53 which are 
capable of independent functional interactions and highlighted the efficacy of this approach 
to discriminate biological active p53 GSEs from a random fragment library. This work may 
have use in the rational design of low molecular mass modifiers of the p53 response.
Both G1 arrest and apoptosis induced by ionising radiation or cisplatin are dependent 
upon an intact p53-mediated DNA damage response pathway in the A2780 line. Evidence 
is presented for a defect in the p53-mediated DNA damage response pathway in cisplatin 
resistant derivatives of A2780 cells as determined by reduced DNA damage induced G1 
arrest, apoptosis and transcription of certain target genes (Chapter 3). The basis of the 
p53 dysfunction in one of these resistant cell lines does not appear to be due mutation of 
the TP53 gene, overexpression of mdm2 protein, differences in the cell cycle related 
expression of p53 protein or gross changes in the pattern of p53 isoforms. Cisplatin 
resistant A2780 derivatives also acquire a microsatellite instability (RER+) phenotype, 
which is associated with defective mismatch repair (MMR) and loss of hMLHl mRNA and 
protein expression. Defective MMR in these cisplatin resistant cells may lead to tolerance 
of DNA damage and reduced ability to engage both p53-dependent and -independent 
apoptotic pathways.
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1.1 p53-MEDIATED DNA DAMAGE RESPONSE PATHWAY
Resistance of tumour cells to radiation and chemotherapy remains a significant obstacle 
in the effective treatment of cancer. DNA is the primary target for many antitumour 
agents. A wealth of evidence has supported a role for p53 in the cellular response to 
DNA damage (see reviews: Ko and Prives, 1996; Shimamura and Fisher, 1996). DNA 
damage induced activation of p53 can result in either cell cycle arrest or apoptosis 
(Figure 1). Furthermore, p53 may also modulate DNA replication and DNA repair. In 
response to DNA damage, p53 protein accumulates and can activate (or repress) the 
transcription of a variety of target genes which may mediate its biological effects. 
Alternatively, p53 may directly interact with and effect critical proteins involved in the 
above processes in a transcriptionally-independent manner. The decision between p53- 
mediated arrest or apoptosis is at least partially influenced by cell type and environment 
It must be noted that in addition to its response to genotoxic stress, p53 may mediate a 
more general response to suboptimal growth conditions (Donehower and Bradley, 1993). 
For example, both hypoxia and heat induce p53, as does starvation (Zhan et al., 1993; 
Graeber et a l, 1994). In addition, ribonucleotide depletion has been shown to induce a 
























Figure 1. The p53-dependent DNA damage response pathway.
1.1.1 STRUCTURE AND FUNCTION
The human p53 protein is a complex molecule composed of 393 amino acids and with an 
ever increasing number of functional domains identified (see reviews: Deppert, 1994; 
Harris, 1996). The N-terminus (residues 1-42) contains a large number of acidic residues 
and harbours a transcriptional activation domain (Unger et a l, 1992). However, 
neighbouring sequences are also likely to contribute to the transcriptional activity of p53 
(Chang et a l , 1995a). Adjacent to the N-terminus is a proline-rich region spanning amino 
acids 61-94 which represents a putative target site for SH3 domain binding proteins. In 
fact, recent evidence has suggested that this SH3-like domain within p53 may play a role 
in transcription-independent protein signalling and growth suppression (Walker and 
Levine, unpublished observations).
The sequence-specific DNA binding domain (residues 100-290) is located within 
the central core of p53 (Cho et al. , 1994). The majority of p53 missense mutations which 
occur in human tumours are clustered within this area, particularly within the conserved 
regions of homology II-V (Hollstein et al., 1994). The C-terminus of p53 can function as 
an independent domain capable of binding non-specifically to different forms of DNA, 
including damaged DNA (Wang et al, 1993; Lee et a l, 1995; Reed et al., 1995). A 
flexible "linker" region (residues 290-310) connects the sequence-specific DNA binding 
domain to the oligomerisation domain which spans amino acids 320-360. X-ray crystal 
structures of both the sequence-specific DNA binding and oligomerisation domains have 
been resolved (Cho et a l, 1994; Jeffrey et a l, 1995). At the extreme C-terminus is a
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stretch of 30 amino acids that is rich in basic residues and which negatively regulates the 
sequence-specific DNA binding activity of p53 (Hupp et al. , 1992).
1.1.2 THE SIGNAL
The focus of much current interest is the elucidation of how signals are transmitted from 
damaged DNA to activate the p53 pathway. One of the initial inducing signals for p53 
accumulation in response to damage appears to be double strand breaks (DSBs; Nelson 
and Kastan, 1994). In fact, it has been predicted that even a single DSB is enough to 
induce p53 (Di Leonardo et al. , 1994). However, a signal transduction pathway linking 
the presence of DSBs to p53 accumulation has yet to be identified. The suggestion that a 
regulated kinase cascade may, at least in part, be responsible for controlling this process 
is based upon the observation that inhibitors of PKC and serine/threonine phosphatases 
can prevent radiation induced p53 responses (Khanna and Lavin, 1993). Triggering of 
the p53 response may require DNA metabolism, although either replication or repair may 
suffice (Cox and Lane, 1995).
Other lesions apart from DBSs have been demonstrated to activate the p53 arrest 
pathway (Huang et al., 1996). Nuclear injection of linearised plasmid DNA, circular 
DNA with a gap of larger than 30 nucleotides or single-stranded circular phagemid was 
sufficient to induce a p53-dependent G1 arrest in normal human fibroblasts. However, 
both supercoiled and nicked plasmid DNA and circular DNA with a 25 nucleotide gap 
were ineffective. It was suggested that the difference in arrest potential of 25 and 30 
nucleotide gaps is consistent with the potential involvement of the nucleotide excision
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repair (NER) machinery in activating the arrest mechanism. Interestingly, dumbbell 
substrates containing single mismatched bases (which are recognised and corrected by 
the mismatch repair machinery) also produced a p53-dependent G1 arrest (Wahl et a l , 
personal communication).
1.1.3 MECHANISMS OF ACCUMULATION
Activation of p53 results in increased p53 protein levels which is generally agreed to 
occur through a post-transcriptional mechanism (Kastan et a l, 1991). Furthermore, p53 
induction appears to be cell type specific (Midgley et al. , 1995). The ATM gene product, 
although not required for p53 induction, can influence the timing of this process (Enoch 
and Norbury, 1995). An alternatively spliced form of human TP53 mRNA has recently 
been identified in normal lymphocytes (Flaman et a l, 1996). This splice variant lacks a 
major portion of the C-terminus which may have significant implications for its activity. 
Intriguingly, p53 may also be negatively autoregulated by specifically inhibiting 
translation of its own mRNA (Mosner et a l , 1995).
Levels of p53 protein are usually quite low in normal cells, due in part to its rapid 
turnover. Ubiquitin-dependent proteolysis has been shown to play a significant role in the 
degradation of p53 protein (Maki et a l, 1996). After treatment with DNA damaging 
agents, the half-life of p53 becomes markedly extended (Matlzman and Czyzyk, 1984; 
Kastan et a l, 1991; Liu et a l, 1994). It is assumed that this increase in p53 stability 
represents the major mechanism for p53 accumulation after DNA damage. However, the 
molecular basis of p53 stabilisation has not been clarified but may result from changes in
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post-translational modification, oligomerisation and binding to other proteins. Alteration 
of ubiquitin-dependent proteolytic degradation of p53 protein is another likely possibility. 
Interestingly, when complexed with DNA, p53 is resistant to ubiquitin-dependent 
proteolysis, whereas unbound protein undergoes rapid degradation (Molinari and Milner,
1995).
1.1.4 MODULATORS OF FUNCTION
In addition to increasing p53 protein levels, cells may respond to DNA damage by 
modulating the function of the protein in a variety of ways including phosphorylation, 
redox regulation, nuclear targeting and protein-protein association. The human p53 
protein is multiply phosphorylated by a number of protein kinases at serines and 
threonines within its N- and C-termini in vitro and in cell lines (see review: Meek, 1994). 
Phosphorylation may affect p53 by altering turnover rate and activity. In fact, 
hyperphosphorylation of p53 using the serine phosphatase inhibitor okadaic acid 
increased the steady-state level of p53 protein (Zhang et a l, 1994). The sequence- 
specific DNA binding activity of p53 can be stimulated in vitro by phosphorylation using 
a number of different protein kinases (Hupp et a l, 1992; Takenaka et a l, 1995; Wang 
and Prives, 1995). Indeed, p53 has been shown to be phosphorylated by a UV damage 
inducible protein kinase (Milne et al., 1995). However, conflicting results have emerged 
from studies which examined the effect of mutation of certain phosphorylation sites on 
p53 function (Ko and Prives, 1996). While some studies have demonstrated alterations in
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p53 function as a result of mutation of phosphorylation sites, others have shown no 
effect. Therefore, the full relevance of p53 phosphorylation remains to be elucidated.
The sequence-specific DNA binding activity of p53 is subject to redox regulation. 
Oxidation of p53 inhibits DNA binding, whereas reduction favours it (Hupp et a l , 1993; 
Rainwater et al. , 1995). Furthermore, oxidation also abolishes the ability of p53 to block 
nuclear DNA replication in vitro (Cox et a l, 1995). The balance between oxygen 
radicals induced by genotoxic stresses such as ionising radiation and cellular reducing 
responses may have important implications for regulation of p53 function (Hainaut and 
Milner, 1993). Subcellular localisation can provide an important mechanism of regulating 
p53 function. Indeed, translocation of p53 protein to the nucleus was shown to be 
required for p53 to induce a cell cycle arrest following DNA damage (Shaulsky et a l , 
1991). Cytoplasmic protein anchors may act to prevent p53 from entering the nucleus 
(Gannon and Lane, 1991). An ever increasing number of cellular proteins have been 
reported that bind to p53 protein. Some of these interactions may be intimately linked 
with regulation of p53 function. A prime example is the MDM2 oncogene which encodes 
a protein that can complex with p53 and inhibit its transcriptional activation ability 
(Momand et a l , 1992; Oliner et a l , 1993). Furthermore, MDM2 itself is a transcriptional 
target of p53 and is activated in response to radiation, thus implying an autoregulatory 
feedback loop between p53 and MDM2 (Wu et a l , 1993).
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1.1.5 TRANSCRIPTIONAL ACTIVATION (REPRESSION)
A large body of evidence has indicated that the sequence-specific transcriptional 
activation function of p53 is a major component of its biological effects (Ko and Prives,
1996). Transcriptional activation of specific target genes by p53 may lead to a number of 
cellular outcomes including DNA repair, cell cycle arrest and apoptosis (explored in 
more detail in the following subsections). Molecules of p53 bind as tetramers to highly 
degenerate DNA motifs which are found generally in the control regions of target genes. 
These binding sites permit both position- and orientation-independent activation by p53. 
In addition, both p53 oligomerisation and DNA looping have been associated with the 
transcriptional activation function of p53 (Stenger et a l, 1994). Intriguingly, recent data 
has emerged which suggests that certain p53 mutants may be able to discriminate 
between various target gene promoters and therefore have differential effects on 
transcriptional activation of these genes (Friedlander et a l , 1996; Ludwig et a l , 1996).
p53 also represses the transcription of a number of cellular genes in a manner 
which is independent of specific DNA recognition (Ko and Prives, 1996). Examples of 
genes whose expression is repressed by p53 include BCL-2, FOS and PCNA (Kley et a l , 
1992; Jackson et a l, 1994; Miyashita et a l, 1994). As these genes lack obvious p53- 
binding sites in either promoter or enhancer regions, p53 is believed to act as a broad- 
range repressor. However, only those promoters which contain TATA boxes appear to 
be inhibited by p53 (Mack et a l, 1993). The C-terminus of p53 is required for 
transcriptional repression and interaction with the TATA-binding protein, TBP
10
(Horikoshi et a l, 1995; Shaulian et a l , 1995). Indeed, p53 may repress transcription 
through a squelching mechanism in which TBP is sequestered from promoter sites by 
interaction with p53 thus causing reduced initiation of transcription.
1.1.6 CELL CYCLE ARREST
The role of p53 in regulating the Gl/S cell cycle checkpoint in response to DNA damage 
is well documented (Shimamura and Fisher, 1996). A major effector of the p53-mediated 
G1 arrest is thought to be the CIP1/WAF1 gene (El-Deiry et a l, 1993; Harper et a l, 
1993; El-Deiry et a l, 1994). The CIP1 gene is a transcriptional target for p53 and 
contains two p53-binding sites - one close to the TATA box and the second several 
kilobases upstream. The encoded protein p21 forms part of a quaternary complex found 
in normal cells along with cyclin, cyclin-dependent kinase (CDK) and PCNA (Xiong et 
a l, 1993). Induction of CIP1 expression by activated p53 was shown to inhibit the 
function of those cyclin/CDK complexes which are predominantly found during G1 phase 
of the cell cycle (Dulic et a l, 1994). Such inhibition results in the accumulation of 
hypophosphorylated Rb protein thus inducing a G1 arrest (Slebos et a l, 1994). In 
addition, CIP null cells displayed a defective G1 arrest in response to radiation treatment 
(Brugarolas et a l, 1995; Deng et a l, 1995). It must be noted that expression of CIP1 is 
also regulated by p53-independent mechanisms (Michieli et a l, 1994; Macleod et a l, 
1995). p53 has also been suggested to play a potential role in the control of the G2/M 
cell cycle checkpoint (Agarwal et a l , 1995; Stewart et a l , 1995).
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1.1.7 APOPTOSIS
Substantial evidence has accumulated to suggest that p53 is a positive regulator of cell 
death, and particularly of apoptosis (Oren, 1994). Cells obtained from TP53 null mice 
were shown to be resistant to the induction of apoptosis by radiation and chemotherapy 
(Clarke et a l, 1993; Lowe et a l, 1993a; Lowe et a l, 1993b). Indeed, the effectiveness 
of a variety of cancer therapies in vivo correlated with the ability to induce a p53- 
dependent apoptotic response (Lowe et a l, 1994). However, it must be noted that 
apoptosis can also occur by pathways independent of p53 (see review: Liebermann et a l , 
1995). The BAX gene is a transcriptional target of p53 and encodes a protein with 
homology to the survival factor encoded by the BCL-2 oncogene (Miyashita and Reed, 
1995). In addition, expression of BCL-2 is repressed by p53 (Miyashita et a l, 1994). 
Both bcl-2 and bax proteins can heterodimerise and the relative levels of these proteins 
(and possibly other family members) are critical to the regulation of the apoptotic process 
(White, 1996). Some studies have indicated that p53 may also have a transcription- 
independent function in apoptosis (Caelles et a l, 1994; Wagner et a l, 1994). Recent 
evidence has suggested that, in response to DNA damage, p53 binding to the 
transcription-repair complex TFIIH either modulates DNA repair efficiency or triggers 
apoptosis (Wang et a l , 1996).
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1.1.8 DNA REPLICATION AND REPAIR
p53 may have a direct impact on DNA replication and repair through its function as a 
transcriptional activator. The encoded products of two different target genes, CIP1 and 
GADD45, have been shown to interact with PCNA, a factor that is involved in both 
DNA replication and DNA repair (Flores-Rozas et a l, 1994; Smith et al., 1994). The 
p21 protein has been shown to directly inhibit the function of PCNA in replication, 
although its function in repair is relatively unaffected (Li et al. , 1994; Waga et al., 1994). 
p53 may also directly regulate DNA replication and repair in a manner independent of its 
transcriptional activation function. In this respect, p53 can bind to several proteins which 
may be involved in the above processes most notably RPA, several components of the 
TFIIH complex (p62, XPB and XPD) and the strand-specific repair factor CSB (Dutta et 
al., 1993; Li and Botchan et al., 1993; Wang et a l, 1995; Leveillard et al., 1996 and 
references therein).
Direct inhibition of nuclear DNA replication by p53 has been demonstrated in 
vitro (Cox et al., 1995; Miller et al., 1995). A 3'—>5' exonuclease activity has been 
recently described for p53 which may be involved in processes of damage avoidance 
and/or error correction during DNA replication and repair (Mummenbrauer et al., 1996). 
Recent data by our group has suggested that p53 may function in a signalling pathway 
downstream of mismatch repair (Anthoney et a l, 1996). However, there is some 
evidence which argues against a role for p53 in DNA replication and repair. The 
interactions of p53 with RPA and TFHH may relate to its function as a regulator of
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transcription rather than DNA replication or repair. While deficiency of p53 function has 
been shown to result in reduced repair of cellular DNA in some cases (Ford and 
Hanawalt, 1995; Smith et a l, 1995; Wang et a l, 1995; Rafferty et a l, 1996), other 
studies have demonstrated that cells from TP53 null mice display normal rates of DNA 
repair as wild-type cells (Ishizaki et a l , 1994; Sands et a l , 1995).
1.1.9 CELL TYPE AND ENVIRONMENT
Cell type and environment seem to be major determinants of whether p53 responds to 
DNA damage by inducing cell cycle arrest or apoptosis (Bates and Vousden, 1996). 
Thymocytes entered apoptosis in response to DNA damage through a p53-dependent 
pathway (Clarke et a l, 1993; Lowe et a l, 1993b). However, irradiation of normal 
fibroblasts resulted in a prolonged p53-dependent G1 arrest (Di Leonardo et a l, 1994). 
Oncogenically transformed fibroblasts showed a shift in the DNA damage induced p53 
response from cell cycle arrest to apoptosis (Lowe et a l, 1993a). Alterations in cellular 
environment, particularly the presence or absence of survival factors, resulted in a similar 
shift in the p53 response (Collins et a l, 1992; Canman et a l , 1995). Intriguingly, certain 
p53 mutants have been shown to maintain the ability to induce a G1 arrest but display 
impaired apoptotic functions (Friedlander et a l, 1996; Ludwig et a l, 1996; Rowan et 
a l , 1996). These results demonstrate that cell cycle arrest and apoptosis mediated by p53 
can be separated and suggest that these pathways are independent of each other. Overall, 
the decision to undergo cell cycle arrest or apoptosis in response to DNA damage will 
have important ramifications for the response of tumour cells to therapy.
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1.2 CISPLATIN
1.2.1 CISPLATIN AS A CHEMOTHERAPEUTIC AGENT
Despite many recent advances in understanding the molecular basis of cancer, treatment 
of human cancer is still limited by the toxicity of chemotherapeutic agents and the 
development of intrinsic or acquired resistance to these drugs. Cis- 
diamminedichloroplatinum(II) or cisplatin has become the primary building block for 
regimens that cure patients with testicular carcinoma and produces high response rates in 
patients with non-small cell lung, bladder, and ovarian cancer among others (Rosenberg, 
1985). However, the development of resistance to cisplatin in the clinic represents a 
major problem in long term treatment of these diseases. Elucidation of the molecular 
basis of cisplatin resistance may help in the design of rational approaches to circumvent 
this problem.
Cisplatin was initially discovered during a study into the effects of electric current 
on growing bacteria (Rosenberg et a l, 1965). It was observed that when an alternating 
current was delivered through platinum electrodes to a growing culture of Escherichia 
coli, the bacterial cells stopped dividing and grew into long filaments. Upon further 
investigation, a compound was identified which formed from the electrodes during 
electrolysis and inhibited cell division - the platinum coordination complex cis- 
Pt(H) (NH3)2C12 or cisplatin. This compound was shown soon afterwards to have potent 
antitumour activity (Rosenberg et a l , 1969). Cisplatin is a bifunctional alkylating agent
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which can form covalent adducts with many biological molecules including RNA, DNA 
and proteins. However, most data are consistent with the hypothesis that the major 
cytotoxic target of cisplatin is DNA (Fram, 1992). Perhaps, the most compelling 
evidence comes from experiments showing that both prokaryotic and eukaryotic cells 
deficient in DNA repair were hypersensitive to cisplatin (Beck and Brubaker, 1973; Chu, 
1994).
But the type of DNA lesions primarily responsible for the cytoxicity and 
antitumour activity of cisplatin are not clearly established. Cisplatin forms a variety of 
DNA lesions including monofunctional adducts and both interstrand and intrastrand 
crosslinks (Zamble and Lippard, 1995). The most prevalent DNA adduct (>90%) formed 
by cisplatin is the 1,2-intrastrand crosslink, where platinum is covalently bound to the N 
positions of adjacent purine bases. The chemotherapeutically inactive trans geometrical 
isomer of cisplatin cannot form the 1,2-intrastrand crosslink suggesting that this lesion 
may be responsible for the antitumour activity of cisplatin (Connors et al., 1972). 
Furthermore, the 1,2-intrastrand crosslink was shown to be poorly repaired by NER in 
vitro and such inefficient repair may increase cellular toxicity (Szymkowski et al. , 1992). 
Formation of cisplatin-DNA adducts has important structural implications, e.g. in case of 
the 1,2-intrastrand crosslink, the DNA is unwound and bent towards the minor groove 
(Anin and Leng, 1990). Changes in DNA topology induced by cisplatin have the 
potential to affect the ability of the DNA to be used as a template for cellular processes 
such as DNA replication and gene transcription.
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1.2.2 TUMOUR CELL LINES AS MODEL SYSTEMS
Cell culture model systems may be useful in the elucidation of the molecular mechanisms 
of both intrinsic and acquired drug resistance. Advantages of such experimental systems 
include ease of manipulation and precise control of external factors. Cell lines can be 
established from tumour cells which show intrinsic resistance to cisplatin. Acquired 
cisplatin resistance can be studied by making drug resistant variants of inherently 
sensitive cells. This process normally requires continuous exposure to increasing 
concentrations of cisplatin over a period which can encompass several years (Behrens et 
al. , 1987). A possible disadvantage in using multiple step selection is that these drug 
resistant variants are destined to show a variety of resistance mechanisms making the 
task of dissecting out each pathway more difficult. Single step selection with cisplatin has 
also proven effective in the isolation of drug resistant variants (McLaughlin et al. , 1991). 
Cell lines generated in this way would be expected to display a single mechanism of 
resistance. The resistance phenotype of either single or multiple step selected cell lines is 
generally stable for long periods in the absence of selective medium (Thompson and 
Baker, 1973).
An important consideration is how relevant such in vitro ceil line models are to 
clinically observed drug resistance. Extrapolating results from in vitro systems can be 
difficult as the repeated high levels of cisplatin used for selection of resistant tumour cell 
lines often bare little resemblance to those used clinically and the large fold resistance 
frequently studied using certain in vitro models may be unrepresentative of the low levels
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of resistance that can lead to treatment failure. Another more direct, albeit artificial, 
approach is genetic intervention of tumour cells i.e. overexpression or inactivation of 
genes which may play a role in the response of cells to cisplatin.
1.2.3 MOLECULAR MECHANISMS OF RESISTANCE
Investigations at the cellular level have shown cisplatin resistance to be due to one or 
more of a number of mechanisms including decreased drug accumulation, increased 
cytoplasmic detoxification, alterations in signal transduction pathways and aberrant DNA 
damage induced responses (Figure 2; Ishida et a l, 1995). Decreased intracellular 
cisplatin accumulation, resulting from reduced influx or increased efflux of the drug, has 
been observed in many cisplatin resistant tumour cell lines (Andrews and Howell, 1990). 
However, the causative molecular mechanism (s) underlying decreased cisplatin 
accumulation is as yet unclear. A number of reports have indicated that cisplatin enters 
cells through passive diffusion (Gale et a l , 1973; Ogawa et al. , 1975). Nevertheless, it is 
unlikely that changes in the passive permeability of the plasma membrane is responsible 
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Figure 2. Molecular mechanisms of cisplatin resistance.
Evidence suggesting the existence of an active transporter for cisplatin has been 
increasing. In one particular study, a 200kDa membrane glycoprotein was identified in a 
cisplatin resistant derivative of the murine R l.l lymphoma cell line, which is distinct from 
the multidrug resistance-associated P-glycoprotein (Kawai et a l, 1990). Elevated levels 
of the 200kDa glycoprotein correlated with reduced cisplatin accumulation in this 
resistant line. Determination of the exact contribution of the 200kDa glycoproten to 
cisplatin resistance will require further experimentation (Bernal et a l, 1990). In vivo 
studies of cisplatin resistance have also been performed. Human ovarian 2008 carcinoma 
cells were made resistant to cisplatin (1.4-2.2 fold) as xenografts in athymic mice 
(Andrews et a l, 1990). These resistant cells showed a 28% decrease in cisplatin 
accumulation.
Intracellular detoxification of cisplatin may occur by binding to sulfhydryl 
peptides, small thiol-rich proteins or heat-shock proteins. Cisplatin, being an electrophilic 
molecule, is extremely reactive toward sulfur-containing nucleophiles. Glutathione 
(GSH), the principal cellular sulfhydryl peptide, has many important functions including 
protection from oxidative stress, drug metabolism and intracellular detoxification 
(Meister and Anderson, 1983). Although levels of GSH are commonly increased in 
cisplatin resistant tumour cell lines, the role of GSH in mediating resistance to cisplatin 
remains unclear (Andrews and Howell, 1990; Ishida et a l, 1995). Elevated GSH levels 
were only observed in resistant cells selected by continuous exposure to cisplatin in vitro. 
It is possible that the increased GSH levels may be due to a general stress response to 
drug treatment and are not directly involved in inducing cisplatin resistance.
20
Metallothioneins (MTs) are small, thiol-rich proteins important in binding and 
detoxifying heavy metals (Hamer, 1986). Elevated levels of MTs have been observed in 
certain cisplatin resistant cell lines (Kelly et a l, 1988; Kasahara et al., 1991). But, 
examination of MT levels in ovarian tumours before and after chemotherapy revealed 
that MT content was not a major determinant of tumour sensitivity (Murphy et al., 
1991). Heat-shock proteins (HSPs) are a unique set of highly conserved proteins, 
induced by exposure to heat and a variety of other types of stress, which are presumed to 
confer a protective function to the cell (Parsell and Lindquist, 1993). 2008 cells selected 
for cisplatin resistance by chronic in vitro exposure expressed increased levels of HSP60 
mRNA and protein (Kimura et al., 1993). In fact, the level of HSP60 mRNA expression 
may be a valuable prognostic factor for epithelial ovarian cancer treated with platinum 
compounds (Kimura et a l , 1992).
The folate cycle provides an important source of deoxythymidylate molecules 
which are essential for DNA synthesis and repair (Voet and Voet, 1990). A number of 
cisplatin resistant cell lines have exhibited alterations in folate metabolism (Andrews and 
Howell, 1990). Human ovarian A2780 carcinoma cells made resistant to cisplatin (3.2 
fold) by discontinuous exposure showed 2.5 fold increases in thymidine kinase, 
thymidylate synthase and dihydrofolate reductase activities (Scanlon et a l, 1989a). 
Similar changes were observed with cisplatin resistant human colon HCT8 carcinoma 
cells (Scanlon et a l, 1989b). Data from clinical samples suggested that changes in folate 
metabolism may arise in cisplatin resistant tumours also (Scanlon et al. , 1989a).
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Cell growth and differentiation can be initiated by signal cascades which are 
commonly altered in human cancer (Cantley et al., 1991). Chemotherapeutic agents have 
been shown to encroach upon on these signal transduction pathways which may lead to 
the evolution of drug resistant clones (Brunton and Workman, 1993). Several 
components of cellular signalling pathways have been implicated in cisplatin resistance 
mechanisms including ras and fos among others (Ishida et al. , 1995). Overexpression of a 
mutant c-Ha—RAS gene conferred cisplatin resistance in NIH 3T3 cells, which was 
associated with an impairment of intracellular drug accumulation and an increase in 
metallothionein content (Isonishi et al., 1991). Increased expression of FOS has been 
observed in cisplatin resistant tumour cell lines and in patients (Scanlon et al., 1989a). A 
FOS ribozyme has also been shown to completely reverse cisplatin resistance in certain 
tumour cell lines, possibly through downregulation of AP-1 responsive genes such as 
thymidylate synthase, topoisomerase I and metallothionein (Scanlon et al., 1991). In 
contrast, activation of both PKA and PKC enhanced sensitivity of certain tumour cells to 
cisplatin (Christen et al., 1994).
A variety of resistance mechanisms may operate after cisplatin induced DNA 
damage including enhanced DNA repair, increased damage tolerance, aberrant cell cycle 
arrests and reduced apoptosis (Brown et al., 1995). DNA repair plays an integral role in 
the molecular mechanism of cisplatin action (Zamble and Lippard, 1995). Cells derived 
from Xeroderma pigmentosum patients, which are deficient in NER, were shown to 
display hypersensitivity to cisplatin (Plooy et al., 1985). Moreover, it has been shown 
that both the 1,2- and 1,3- intrastrand crosslinks are repaired by the NER pathway
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(Huang et a l, 1994). However, repair of the 1,2-intrastrand crosslink is relatively 
inefficient in comparison to other platinum-DNA lesions (Szymkowski et a l, 1992). 
Enhanced DNA repair has been demonstrated in a variety of tumour cell line models with 
either intrinsic or acquired resistance to cisplatin (Sheibani et a l, 1989; Parker et a l, 
1991). Interestingly, increased gene-specific repair interstrand crosslinks has been 
observed in certain cisplatin resistant human ovarian cancer cell lines (Zhen et a l , 1992). 
It has been suggested that the increase in DNA repair that accompanies cisplatin 
resistance may be due to altered expression of proteins involved in NER such as ERCC1 
and PCNA (Haneda et a l , 1991; Dabholkar et a l , 1992).
Proteins, termed DNA damage recognition proteins (DRPs), have been identified 
which specifically bind to cisplatin-DNA adducts and are overexpressed in cisplatin 
resistant tumour cells (McLaughlin et a l, 1993; Chu et a l, 1994). Subsequent studies 
revealed that such DRPs contain HMG-domains which recognise DNA structural 
elements, such as the bends in cisplatin-modified DNA (Zamble and Lippard, 1995). 
HMG-domain proteins may serve as recognition elements for repair and act by recruiting 
other proteins in the NER complex to sites of DNA damage. An alternative hypothesis is 
that HMG-domain proteins bind tightly to cisplatin-DNA adducts and prevent access of 
the repair complex to the site of damage. Increased tolerance of cisplatin-DNA adducts 
may play an important role in cisplatin resistance of human tumour cells (Parker et a l, 
1991; Mamenta et a l , 1994). Enhanced replicative bypass (the ability to synthesize DNA 
past the site of DNA damage) has been proposed as a potential mechanism leading to 
adduct tolerance.
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DNA damaging agents can induce arrest of proliferating cells at several points in 
the cell cycle. Such cell cycle arrests have been proposed to allow sufficient time for 
repair of potentially lethal damage (Hartwell, 1992; Lane, 1992). However, it is also 
possible that these arrests may be prerequisite events necessary for programmed cell 
death mechanisms. Cisplatin induces a number of cell cycle perturbations including a 
slow down in S-phase transit and a dose-dependent arrest in G2 (Demarcq et al., 1992; 
Ormerod et al., 1994). In fact, the presence of a G2 arrest has been shown to be crucial 
in allowing cell death to occur by apoptosis in response to cisplatin (Eastman, 1990). 
Therefore, loss of a cisplatin induced G2 arrest in cisplatin selected cell lines may be a 
possible mechanism of increased resistance. Data concerning the existence of a cisplatin 
induced G1 arrest is controversial (Brown et al., 1995). Some cell cycle studies on 
cisplatin treatment of mammalian cells exhibit no evidence of a G1 arrest induced by 
cisplatin (Demarcq et al., 1992; Ormerod et al., 1994).
In contrast, work from our laboratory showed that A2780 cells, which possess 
wild-type p53 and a functional ionising radiation induced G1 arrest, arrested at G1 after 
exposure to cisplatin (Brown et al., 1993). In fact, this cisplatin induced G1 arrest was 
lost after transfection of a dominant negative p53 mutant (codon 143, Val to Ala) into 
these cells, which is known to abrogate an ionising radiation induced G1 arrest 
(Mcllwrath et a l, 1994; Vasey and Brown,personal communication). Such mutant p53 
transfectants were more resistant to ionising radiation and cisplatin than vector alone 
controls (Mcllwrath et a l, 1994; Vasey et al., in press). Loss of a radiation induced G1 
arrest and aberrant p53 protein expression have been observed in certain human ovarian
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tumour cell lines selected for resistance to cisplatin (Brown et a l, 1993). These 
observations suggested that loss of p53 function may be associated with acquisition of 
cisplatin resistance. However, genetic inactivation of p53 in human breast MCF-7 cancer 
cells increased sensitivity to cisplatin (Fan et al., 1995). These cells also displayed a 
reduced ionising radiation induced G1 arrest and it has been proposed that the increase in 
cisplatin sensitivity is due to reduced DNA repair. These apparently contradictory results 
may be explained by cell type or environmental differences between these model systems 
(see subsection 1.1.9 for more details).
Reduced apoptosis in response to DNA damage has been postulated as one of the 
molecular mechanisms leading to increased cisplatin resistance (Brown et al., 1995). 
Cisplatin has been shown to induce apoptosis in a variety of cell systems (Evans and 
Dive, 1993; Gorczyca et al., 1993a). As mentioned, the G2 arrest induced by cisplatin 
may be intimately linked with the ability of a cell to undergo apoptosis. However, the 
mechanism controlling the decision to enter apoptosis at G2 has still to be established. 
Intriguingly, cisplatin has been shown to induce rapid apoptosis in proliferating, but not 
quiescent, thymocytes (Evans et al., 1994). Consequently, it has been proposed that for 
cisplatin induced cell death to occur, either progression is required through specific 
points in the cell cycle prior to entry into apoptosis or proliferation/DNA replication are 
necessary to convert DNA damage induced by cisplatin into a form that activates an 
apoptotic response (Brown et a l, 1995).
Immature thymocytes from TP53 null mice and dominant negative p53 mutant 
(codon 143, Val to Ala) transfectants of A2780 cells both displayed a reduced ability to
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undergo apoptosis in response to cisplatin (Vasey et a l, in press). Introduction of wild- 
type p53 into human TP53 null lung cancer cells increased sensitivity to cisplatin 
(Fujiwara et al., 1994). Notably, an increased level of cisplatin induced apoptosis was 
observed in these cells. Recent evidence has suggested an association between the 
development of cisplatin resistance, mutation of the TP53 gene and reduced BAX 
expression in ovarian cancer (Perego et a l, 1996). Furthermore, exogenous expression 
of BCL-2 in A2780 cells resulted in protection from cisplatin induced apoptosis 
(Eliopoulos et a l, 1995). Cisplatin has been shown to induce the expression of 
interleukin 1 (3-converting enzyme (ICE), a mammalian homologue of the Caenohabiditis 
elegans cell death gene CED-3 (Kondo et a l, 1995). Interestingly, the induction of ICE 
by cisplatin was independent of p53. In summary, cisplatin can induce apoptosis through 
both p53-dependent and -independent pathways.
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1.3 GENETIC SUPPRESSOR ELEMENTS
1.3.1 CONCEPT AND BACKGROUND
Genetic suppressor elements (GSEs) are short DNA fragments that induce a biological 
effect when expressed in cells by encoding either dominant negative mutant peptides or 
antisense RNA molecules (Roninson et al. , 1995). GSEs function to inhibit the activity of 
the gene from which they are derived. Both types of GSE may be generated by random 
fragmentation of the target gene(s) and identified by functional selection for a desired 
phenotype in a suitable cellular system. Selection of GSEs from a single gene allows the 
identification of functional protein domains. In this way, efficient and specific modulators 
of gene function may be developed. GSE selection from multigene libraries may identify 
genes that are involved in the selectable cellular phenotypes, e.g. drug resistance.
Igor Roninson and co-workers initially used bacteriophage k as a model system 
to determine the efficacy of random fragment selection as an approach to isolate GSEs 
(Holzmayer et a l, 1992). Bacteriophage k  efficiently lyses infected E. coli cells, thus 
providing a convenient strategy for selecting GSEs that would interfere with phage 
infection, k DNA was randomly fragmented with DNasel and cloned into a bacterial 
plasmid expression vector. An expression library of k DNA fragments was transformed 
into E. coli cells. The presence of the random fragment expression library resulted in 
increased protection from X-induced lysis. Plasmids extracted from surviving cells were 
individually tested for the ability to render E. coli resistant to k  upon re-transformation.
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Sequence analysis of 51 GSEs isolated by this selection indicated that they were derived 
from eleven different regions of the X genome and encoded either specific peptides or 
antisense RNA molecules. Investigation of these GSEs revealed some previously 
unknown functions of bacteriophage X, including suppression of the cellular X receptor 
by an uncharacterised gene of the phage. These experiments unveiled the power of the 
GSE approach for exposing new biological information, even in a very thoroughly 
investigated system.
1.3.2 GSE SELECTION IN MAMMALIAN CELLS
The methodology for conducting GSE selection in mammalian cells is shown in Figure 3. 
The cDNA of interest is randomly fragmented using DNasel and cloned into a retroviral 
expression vector system. The resulting random fragment expression library is 
transfected into a packaging cell line which produces infectious virus. Viral supernatant is 
collected and used to infect a cell line of interest. Selection of infectant cells for the 
desired phenotype results in enrichment of biologically active GSEs. Putative GSEs are 
isolated and sequenced by PCR amplification using primers spanning the cloning site. 
Verification of a particular phenotypic effect of a GSE must be shown by independent re- 
introduction into the target cell line.
I
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Figure 3. Generalised approach for the isolation of genetic suppressor elements.
Retroviral transduction has a number of advantages over more commonly used 
DNA transfection procedures, primarily the relatively high efficiency of stable gene 
transfer and that most of the recipient cells acquire only a single copy of the integrated 
provirus (Coffin et aL, 1996). One drawback of using retroviral transduction with 
complex libraries is the problem of maintaining equal representation of different clones in 
the library. Therefore, it is important to check for even distribution of proviral inserts in 
every infected cell population.
The first application of GSE selection in mammalian cells was performed using 
drug resistance as the selectable cellular phenotype (Gudkov et al., 1993). A total of 
twelve sense- and antisense-oriented GSEs were isolated from human topoisomerase II 
cDNA which induce resistance in HeLa cells to a number of topo II-interactive drugs, 
including etoposide. Most of the predicted peptides encoded by the sense-oriented GSEs 
were clustered in a region involved in topo II dimerisation and topo II-DNA interactions. 
Consequently, such GSEs are thought likely to interfere with drug induced cleavable 
complex formation (Schneider et al., 1990). Frameshift mutants of two sense-oriented 
GSEs were unable to induce etoposide resistance in HeLa cells indicating that these 
GSEs acted through topo D-derived peptides (Gudkov et al., 1993). Expression of one 
antisense-oriented GSE resulted in a decreased level of topo II protein. These results 
demonstrated that random fragment selection could be efficiently utilised in mammalian 
cells to isolate biologically active GSEs.
This approach was extended to isolate GSEs from a complex population of 
mammalian genes (Gudkov et al., 1994; Kirschling et al., 1994). Normalised cDNA
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libraries were prepared from mouse NIH 3T3 and human HeLa cells. The first GSE 
selection was carried out with the NIH 3T3 library using etoposide (Gudkov et a l, 
1994). Three different GSEs were isolated, one of which encoded antisense RNA for a 
heavy chain of the motor protein kinesin. Although not previously implicated in drug 
response, kinesin was subsequently shown to be downregulated in several etoposide 
resistant cell lines. Therefore, GSE selection exposed a natural mechanism for etoposide 
resistance in mammalian cells. A number of GSEs have been isolated from the HeLa 
library which confer cisplatin resistance (Kirschling et al., 1994). Some of these GSEs 
are derived from unknown genes and others from genes not previously associated with 
drug resistance. Other selectable cellular phenotypes have been employed apart from 
drug resistance to isolate GSEs, including the immortalisation of primary embryo 
fibroblasts (Roninson et a l , 1995). In summary, random fragment libraries obtained from 
total cellular DNA can be used to isolate GSEs derived from previously unknown genes 
and which confer different selectable phenotypes.
1.4 AIMS
This thesis has two main objectives:
1. To characterise the p53-mediated DNA damage response pathway in cisplatin resistant 
derivatives of the human ovarian A2780 carcinoma cell line (Chapter 3).
2. To identify genetic suppressor elements derived from TP53 cDNA which confer 
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2.1 MATERIALS
The following section lists routinely used materials. Less frequently used materials are 
described in the appropriate figure legends.
2.1.1 CHEMICALS
All chemicals were of the highest available quality and were obtained from Gibco BRL, 
BDH Chemicals, Pharmacia LKB, Severn Biotech, Rathbum or Sigma Chemicals.
2.1.2 RADIOCHEMICALS
32(a P)dCTP used for labelling DNA probes was obtained ffom Amersham International.
2.1.3 EQUIPMENT
Routine equipment which would be an integral part of any laboratory is not listed.





























2.1.4 RESTRICTION ENDONUCLEASES AND OTHER ENZYMES
Restriction endonucleases and other enymes were obtained from Gibco BRL and 
Promega.
2.1.5 SIZE MARKERS
DNA size markers 
Phage X (Hindlll) 
lOObp DNA ladder
RNA size markers
0.24-9.5kbp RNA ladder Gibco BRL
Protein size markers
29.5-214kDa prestained Gibco BRL
2.1.6 BUFFERS, SOLUTIONS AND MEDIA 
Where mentioned, autoclaving was carried out at 121°C for 20 minutes.
Blocking solution










0.2M Potassium cacodylate 
2.5mM Tris HClpH 6.6 
2.5mM CoCl2 
0.25mg/ml BSA 
5U Terminal transferase 
0.5nmoles Biotin-dUTP
DEPC treated water (0.1%)
999ml Double distilled water 
lml DEPC
Leave at 37°C for 24h 
Autoclaved solution
DNA loading dye




500mM Tris HC1 pH 7.5 
lOOmM MnCU 
lOmg/ml BSA
High salt lysis buffer 
500mM NaCl 
1% NP-40 









Made with DEPC treated water
L-broth
1% Tryptone 
0.5% Yeast extract 
1% NaCl
MOPS RNA running buffer (lOx)
0.2M 4-(N-Morpholino)propane-sulphonic acid
0.05M Na Acetate pH 7.0
0.01M Na2EDTA
Made with DEPC treated water





1.0% BSA fraction V

















0.05% Bromophenol blue 
0.05% Xylene cyanol 
0.1 Volume of 50% glycerol
RPMI
88ml RPMI-1640 (lOx) 
800ml Sterile distilled water 
26.6ml 7.5% Na(C03)2
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10ml lOOmM Na Pyruvate 
10ml 200mM L-glutamine 
3.5ml 1M NaOH 
100ml Foetal calf serum 
5ml Penicillin/Streptomycin (50mg)
Running gel buffer
1.5M Tris base 
0.4% SDS
pH to 8.9 with concentrated HC1
Running gel (8%)
8ml Running gel buffer






0.5M Tris base 
0.4% SDS
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pH to 6.7 with concentrated HC1
Spacer gel (4%)
3ml Spacer gel buffer






500ml Special liquid medium 
50ml 200mM L-glutamine 











89mM Tris borate 
89mM Boric acid 
2.5mM EDTA
Transfer buffer





360ml Sterile distilled water 
40ml lOxPE
40ml Trypsin (2.5% stock)
Wash buffer










2.1.7 CELL LINES 
A2780
A human ovarian adenocarcinoma cell line derived from an untreated patient received 
from R. F. Ozols and T. C. Hamilton, Fox Chase Cancer Centre, Philadelphia.
A2780/CP70
A cisplatin resistant derivative of A2780 cells isolated after two years selection with 
multiple exposures to the drug. For a more complete description of A2780 and 
A2780/CP70 cell lines see Behrens et al., 1987. Both cell lines have previously been 
shown to express only wild-type p53 (Brown et al. , 1993).
A2780/MCP1-9




An amphotropic virus packaging line derived from NIH/3T3 TK* cells by cotransfection 
with retrovirus packaging construct DNA (pPAM3) and the herpes simplex thymidine 
kinase gene (Miller and Buttimore, 1986).
2.1.8 ANTIBODIES AND IMMUNOLOGICAL REAGENTS
The following is a list of the primary antibodies used for Western blotting and 
immunocytochemistry.
Antigen Antibody Isotype Company
mdm2 IF2 Mouse IgG2b Oncogene Science
p53 DO-1 Mouse IgG2a Oncogene Science
p53 PAbl22 Mouse IgGsb Pharmingen
cyclin E HE12 Mouse IgGi Pharmingen
cyclinBl GNS-1 Mouse IgGi Pharmingen
vinculin VIN-11-1 Mouse IgGi Sigma
BrdUrd Bu20a Mouse IgGi Dako
Anti-mouse IgG horseradish peroxidase-linked (HRPL) rabbit antibody (Amersham) was 
used as a secondary agent in Western blotting studies; whereas anti-mouse IgG 
fluorescein 5-isothiocyanate-conjugated (FITC) goat antibody (Sigma) was used in 
immunocytochemistry approaches.
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2.1.9 PLASMIDS AND MOLECULAR PROBES
The following is a list of the plasmids used for GSE library construction and Northern 
blotting, respectively. Molecular probes were derived from DNA fragments obtained 
using the indicated restriction enzymes.
Plasmid cDNA Probe fragment Reference
pC53-SN3 Human TP53 Baker et al. , 1990
pMT-P53-T Murine TP53 Arai et al. , 1986
pCEP-WAF-l-S Human CIP1 Notl (2100bp) El-Deiry et al., 1993
pFL4-MDM2 Human MDM2 Hindin (870bp) Oliner et al. , 1992
pCRII-GAPDH Human GAPDH EcoRI (720bp) Tso et al., 1985
pLNCX Retroviral Vector Miller and Rosman, 1989
The pLNCX retroviral expression vector plasmid was used in the construction of the 
random fragment p53 DNasel GSE libraries (section 2.10). A schematic representation 
of an integrated LNCX pro virus containing a fragment of TP53 cDNA is displayed in 
Figure 4.
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Figure 4. An integrated LNCX provirus containing a fragm ent of TP53 cDNA.
The LNCX vector carries the NEC) (G 418 resistance) gene transcribed from the long terminal repeat 
(LTR) promoter, mid the cD N A  insert transcribed from die cytom egalovirus (CM V) promoter. Adaptor- 
derived sequences are displayed in red. with translation initiation and termination codons shown in 
yellow . Sequences used as PCR primers for isolation mid sequencing o f  the inserts are underlined.
2.1.10 OLIGOMERS
The following is a list of oligomers used in the generation and characterisation of the 
genetic suppressor element libraries.
Primer A 5 ’-TACCGAATTCAAGCTTATGGATGGATG-3’
Primer B 5 ’-CATCCATCCATAAGCTTGAATTC-3 ’
Primer C 5 ’-t g a g t g a g t g a a t c g a t g g a t c c -3 ’
Primer D 5 ’-TATAGGATCCATCGATTCACTCACTCA-3 ’
Primer E 5 ’-CCTGGAGACGCCATCCAC-3’
Primer F 5 ’ - a g c t a g c t t g c c a a a c c t a -3 ’
2.2 EXTRACTION OF NUCLEIC ACID AND PROTEIN
All work with RNA and DNA was carried out using autoclaved solutions and where 
appopriate DEPC treated solutions and equipment. Disposable gloves and plasticware 
were used throughout. DNA and RNA quantitation was performed using a combination 
of visual assessment on a 1% agarose, lx TBE, 0.25pg/ml ethidium bromide gel when 
run against known standards and spectrophotometrically using ODzeonm. Extraction 
protocols were followed as per the manufacturers instructions.
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2.2.1 RNA EXTRACTION
Total RNA was extracted from monolayer cultures using TRIzol reagent (Gibco).
2.2.2 DNA EXTRACTION
Genomic DNA was extracted from monolayer cultures using the Nucleon I kit (Scotlab). 
Plasmid DNA was extracted from large (50-500ml) and small (l-2ml) scale bacterial cell 
cultures using the Maxi (Qiagen) and SpinBind (Flowgen) kits, respectively.
2.2.3 PROTEIN EXTRACTION
Unless otherwise stated, cells were washed with PBS, then lysed at 4°C for lOmin using 
high salt lysis buffer supplemented with protease inhibitors. The lysate was spun at 
12,000g for lOmin and the supernatant stored at -70°C. Protein content was estimated 
using the BioRad kit method and by comparison of gels stained with Coomasie stain 
[0.2% Coomasie brilliant blue R250 in a 50:50:7 v/v ratio of methanol:H20:glacial acetic 
acid] then de-stained using a 25:68:7 v/v ratio of methanol:H20:glacial acetic acid.
2.3 PREPARATION OF 32P RADIOLABELLED PROBES
2.3.1 RANDOM PRIMING OF DOUBLE-STRANDED DNA
(a32P)dCTP labelled dsDNA probes (50-100ng) were produced with the aid of the 
Prime-Itkit (Stratagene).
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2.3.2 NICK COLUMN PURIFICATION
32 •Radiolabelled probes were separated from unincorporated P-labelled nucleotides using 
disposable NICK columns (Pharmacia).
2.3.3 DETERMINATION OF SPECIFIC ACTIVITY OF PROBE
The specific activity of radiolabelled probes was determined by taking a small aliquot 
(5pl) and measuring the number of disintegrations per minute using a liquid scintillation 
analyzer.
2.3.4 DENATURATION OF PROBES
Probes were denatured before hybridisation by adding 0.1 volume of 3M NaOH and 
leaving for 5min at room temperature. After a 5min incubation on ice with 0.05 volume 
of 1M tris HC1 pH 7.5, 0.1 volume of 3M HC1 was added and left for a further 5min.
2.4 SEPARATION AND HYBRIDISATION OF RNA
2.4.1 SEPARATION AND NORTHERN TRANSFER OF RNA 
Methodology for separation and transfer of RNA emulated instructions detailed in 
Sambrook et a l, 1989. 1.2% (w/v) agarose gels were prepared by dissolving 2.4g of 
agarose in 150ml of water then cooling to 60°C. 19.5ml of lOx MOPS RNA running 
buffer and 36ml of 37% formaldehyde were added and the mixture immediately poured.
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To 20pg of total RNA in 12pl, 25(0.1 formamide, 8(ol formaldehyde and 5(ol lOx MOPS 
RNA running buffer were added. The samples were heated to 65°C for 15min and chilled 
on ice before addition of 5 pi RNA gel loading buffer. After electrophoresis for 4h at 
200V, the gels were imaged by an UV transilliuminator and soaked in 50mM NaOH for 
20min. They were rinsed with DEPC treated water and soaked in 20x SSC for 45min 
prior to transfer onto Hybond-N membranes using 20x SSC as the transfer buffer. 
Membranes were rinsed and exposed to UV for 6min to allow fixation.
2.4.2 HYBRIDISATION OF BLOTS
Pre-hybridisation of blots was carried out at 65°C using hybridisation buffer.
2.4.3 WASHING
Following hybridisation, filters were washed at 65°C using wash buffer until the 
background level of radioactivity was reduced sufficiently.
2.4.4 AUTORADIOGRAPHY
Following washing, blots were blotted dry, wrapped in clingfilm and exposed to Kodak 
AR film in a film cassette with tungstate intensifying screens. Loaded film cassettes were 
held at -70°C until developed.
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2.5 SEPARATION AND IMMUNODETECTION OF PROTEINS
2.5.1 SAMPLE PREPARATION
Protein extracts for one-dimensional gel electrophoresis were prepared and quantified as 
detailed in section 2.2.3. 50pg of total protein was loaded per lane in western loading 
dye after boiling for 3min to facilitate denaturation. Cell extracts were prepared for two- 
dimensional gel electrophoresis using the following protocol. After two washes with 
PBS, 2 x 105 cells were harvested directly into 240pi loading buffer [9.49M urea, 4% 
NP-40, 5.5% ampholytes pH 3-10/2D optimised (Millipore), 0.1% DTT, 0.003% 
bromophenol blue].
2.5.2 ONE DIMENSIONAL GEL ELECTROPHORESIS
Solubilised protein, including size markers, were separated by SDS-polyacrylamide gel 
electrophesis on an 8% running gel after passing through a preliminary 4% stacking gel 
both suspended in lx tank buffer.
2.5.3 TWO DIMENSIONAL GEL ELECTROPHORESIS
Isoelectricfocusing gels [9.5M urea, 2% NP-40, 2% ampholytes pH 3-10, 4% 
polyacrylamide (acrylamide/bis 30.8%T, 2%C), 0.05% APS] were overlayed [0.5M urea, 
0.2% NP-40, 0.1% ampholytes pH 3-10, 5mM DTT, 0.7M 2-mercaptoethanol], and 
prefocused to 1,500V, then loaded (50pi), and run overnight to 18,000Volt hours,
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before being equilibrated [0.3M Tris base, 75mM Tris HC1, 3% SDS, 50mM DTT, 
0.001% bromophenol blue] and run out on polyacrylamide slab gels [10% 
polyacrylamide (acrylamide/bis 30.8%T, 2.6%C), 0.37M Tris buffer pH 8.8, 0.1% SDS, 
0.05% TEMED, 0.025% APS, overlayed with butan-2-ol] at 16W/gel.
2.5.4 WESTERN TRANSFER BY ELECTROBLOTTING
Electroblotting was performed using a semi-dry electroblotter. Immobilin-P membrane 
was immersed in methanol and then transfer buffer. Six sheets of 3M Whatman filter 
paper was sandwiched adjacent to the anode and cathode with the membrane and gel 
layered in between. Transfer took place over lh at 200mA. The gel was stained in 
Coomasie stain overnight and destained as described in section 2.2.3. This allowed a 
visual assessment to be made of the eveness of the transfer and the integrity of the 
proteins.
2.5.5 IMMUNODETECTION OF PROTEINS ON WESTERN BLOTS 
Membranes were incubated with blocking solution at 4°C for 4h, probed overnight in the 
same buffer with primary antibody and washed with 0.1% Tween-20 in PBS. Blots were 
incubated in blocking solution with anti-mouse IgG HRPL rabbit antibody, then washed 
again in 0.1% Tween-20 in PBS, after which bound complexes were visualised by 
enhanced chemiluminescence (Boehringer Mannheim).
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2.5.6 ELISA ANALYSIS OF p53 PROTEIN LEVELS
For ELISA analysis, a sandwich immunoassay was used to measure p53 protein levels in 
cell extracts as described previously (Vojtesek et al. , 1992) with anti-p53 MAb DO-1 as 
the solid-phase reagent and polyclonal rabbit antisera to p53 for the detection of captured 
proteins. Bound complexes were detected using peroxidase-conjugated swine antiserum 
to rabbit immunoglobulin (Dako) and visualised with tetramethylbenzidine; the results 
were then monitored by changes in OD450nm.
2.6 IMMUNOCYTOCHEMISTRY
2.6.1 GENERAL IMMUNOFLUORESCENCE TECHNIQUE
Cells were seeded at 106 cells/lOcm plate and grown for 3-4 days. Fixation was achieved 
24h later when the cells were rinsed with PBS and resuspended in 80% ethanol 
(precooled to -20°C). The samples were centrifuged, washed with PBS and treated with 
0.25% Triton X-100 in PBS for 5min on ice. After addition of 5ml PBS and 
centrifugation, the cells were incubated overnight at 4°C in the presence of mouse 
monoclonal primary antibody which was diluted to 5(-ig/ml in PBT. Cells were washed 
and incubated for 30min with anti-mouse IgG FTTC goat antibody diluted 1:40 in PBT. 
Controls were prepared as described above, except that a mouse isotype specific
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antibody was used instead of the primary antibody. Cells were analysed via flow 
cytometry and confocal microscopy.
2.6.2 CELL CYCLE ASSAY
DNA synthesis was assessed by incorporation of bromodeoxyuridine (BrdUrd) and flow 
cytometric analysis essentially as previously described (Kastan et al., 1991). 
Exponentially growing cells were plated at 5xl05/10cm plate in growth medium and 
incubated for 3-4 days. Cells were either irradiated with y-rays from a 60Co source or 
exposed to cisplatin for lh. At various times after treatment, growth medium was 
replaced by medium containing lOpM BrdUrd and the cells were incubated for 4h at 
37°C. The cells were fixed with ethanol, washed with PBS and resuspended in 1ml 2N 
HC1 for 30min at room temperature. The partially denatured cells were washed twice in 
PBS and once in PBT and then incubated with an anti-BrdUrd MAb Bu20a. The cells 
were washed with PBT and incubated with anti-mouse IgG FTTC goat antibody. After a 
further wash in PBT, cells were analysed via flow cytometry.
2.6.3 APOPTOSIS ASSAY
Apoptotic cells were detected as previously described (Gorczyca et al., 1993b). 
Exponentially growing cells were treated with DNA damaging agents and harvested 72h 
later. Monolayer cells were trypsinised, combined with suspension cells and fixed in 1% 
formaldehyde for 15min on ice. The cells were resuspended in PBS and finally stored in 
70% ethanol at 4°C prior to detection of non-random DNA strand breaks. Cells were
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rehydrated in PBS and aliquots of 106 cells were incubated for 30min at 37°C with 
cacodylate buffer containing terminal transferase and biotin-dUTP. After washing in 
PBS, cells were incubated for 30min at room temperature in the dark with 4x SSC and 
0.1% Triton X-100 containing 5% Marvel and 5p,g/ml H T C -avid in . After a further wash 
in PBS and 0.1% Triton-X, cells were analysed via flow cytometry.
2.6.4 FLOW CYTOMETRY
After F1TC staining, cells were washed with PBS and resuspended in lOp-g/ml of 
propidium iodide (PI) in PBS and stored at 4°C until analysis. Cellular fluorescence was 
measured using a FACScan flow cytometer. The red (PI) and green (FITC) emissions 
from each cell were separated and quantified using the standard optics of the FACScan.
2.6.5 CONFOCAL MICROSCOPY
Small aliquots of cell suspension (20pl) were taken after secondary antibody staining and 
placed onto microscope slides. After dehydration, the slides were mounted with 
Vectashield anti-fade mountant H-1000 (Vector Labs) with 0.3pg/ml PI added. Analysis 
of slides was performed on a laser scanning confocal microscope equipped with a 
krypton/argon ion laser. For FITC and PI, 488/568nm line excitation and dual channel 
522 and 585nm emission filters were used. Image analysis was performed using BioRad 
software.
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2.7 TISSUE CULTURE TECHNIQUES
2.7.1 GENERAL TECHNIQUES
Aseptic manipulations were performed using sterilised glassware in a class II 
microbiological safety cabinet with vertical airflow. Cells were grown at 37°C as 
monolayers in supplemented RPMI medium (Rosswell Park Memorial Institute) in the 
presence of 5% C02. Cells were frozen at a concentration of 106/ml with 10% di-methyl 
sulphoxide (DMSO) at -70°C. After 24h, samples were transferred to liquid nitrogen.
2.7.2 CLONOGENIC ASSAY
Cells were seeded at 103/10cm plate and incubated at 37°C for 24h. Following cisplatin 
treatment, colonies were grown for 10-14 days then stained with Giemsa (BDH) for 
lOmin and rinsed with H20.
2.7.3 MTT ASSAY
Cells were seeded in 96-well plates at 500 cells per well and incubated for 3 days. After 
cisplatin treatment (24h), medium was replenished 3 times every 24h. Relative cell 
numbers were measured using 3-(4,5-dimethiazol-2-yl)-2,5-diphenyl-2//-tetrazolium 
bromide staining as described (Plumb et al. , 1989).
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2.7.4 TRANSFECTION OF CELL LINES WITH PLASMID DNA
Cells were seeded at 106/T75 flask and incubated at 37°C in appropriately supplemented 
SLM for 24h. Medium was replenished 3h before transfection. Plasmid DNA 
(20pg/sample) was introduced into the cells using a standard calcium phosphate 
procedure (Wigler et al. , 1977). After a 24h incubation, the medium containing the DNA 
precipitate was removed and fresh medium added for another 24h. The transfectant cells 
were selected with 750pg/ml G418.
2.7.5 INFECTION OF CELL LINES WITH VIRAL SUPERNATANT
Cell lines to be infected were seeded at 106/T75 flask and incubated at 37°C for 24h. 
Viral supernatant collected from transfected packaging cells was passed through a 
0.45pm sterile filter (Gelman Sciences) and used to infect target cells. Superinfection was 
achieved by repeated addition of virus. After a 24h incubation, the cells were placed 
under selective conditions.
2.7.6 LIPOSOME-MEDIATED PEPTIDE TRANSFER
Synthetic peptides (1 or lOpM final concentration) were transfected into A2780 cells 
using the cationic lipid DOTAP (N- [ 1 - (2,3 -dioleoy loxy) propyl] NJVJV- 
trimethylammoniummethylsulfate: Boehringer Mannheim) at 6pg/ml final concentration 
(Chen et al., 1993). Lipid and peptide mixtures were incubated for 15min at room 




Bacteria were maintained either in liquid culture or on plates under selective conditions. 
Cells were stored for long periods in 15% glycerol in L-broth at -70°C.
2.8.2 TRANSFORMATION OF BACTERIA WITH PLASMID DNA
50-lOOpg of plasmid DNA was added to lOOpl of MAX efficiency DH5a competent 
cells (Gibco) and left on ice for 30 minutes. After a 5min heat-shock at 37°C, 900pl of 
L-broth was added and the samples vortexed before incubation at 37°C for lh. 
Appropriate dilutions were plated on selective medium [1.5% L-agar, lOOpg/ml 
ampicillin] using sterile hockey sticks. Plates were incubated overnight at 37°C.
2.9 GENERAL MOLECULAR BIOLOGY TECHNIQUES
2.9.1 GENERAL PURIFICATION OF DNA
DNA was purified using either of two methods depending upon downstream applications 
- ethanol precipitation or the Wizard DNA clean-up kit (Promega). The former 
procedure required the addition of O.lvol 3M sodium acetate, 2.5vol EtOH and lpl 
glycogen to a sample containing DNA. After precipitation and isolation, the DNA was 
washed with 70% EtOH and resuspended in H20.
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2.9.2 ELECTROELUTION OF DNA FROM AGAROSE
DNA fragments were isolated from agarose gels by electroelution into dialysis bags using 
a previously described protocol (Sambrook et al. , 1989).
2.9.3 REMOVAL OF PRIMERS FROM PCR PRODUCTS
Primer dimers were removed from PCR products using the Wizard PCR preps kit 
(Promega).
2.9.4 STANDARD PCR PROTOCOL
Each standard PCR reaction consisted of lOO-lOOOng template DNA, lx  PCR reaction 
buffer (contains Mg+), 0.8mM dNTP, lpg each primer, 5U Taq DNA polymerase with 
the volume adjusted to lOOp.1. Reactions conditions were as stated in the appropriate 
sections.
2.9.5 AUTOMATED DNA SEQUENCING
Samples were sequenced using the PRISM dye terminator cycle sequencing ready 
reaction kit (ABI). Purified PCR products (300-500ng) were mixed with 3.2pmoles of 
each primer (E and F) in separate reactions and the volume made up to 12pi with H20. 
8 pi of terminator ready reaction mix was added to each sample before undergoing the 
following PCR protocol:
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Preheat to 96°C 
96°C x 15sec 
50°C x lsec 
60°C x 4min 
25 cycles 
Soak 4°C
Excess dye terminators were removed using ethanol precipitation and samples were 
loaded in appropriate buffer on an automated DNA sequencer and run overnight. 
Sequence information was examined using an ABI data analysis program (version 1.2.1).
2.10 GENERATION OF RANDOM FRAGMENT p53 PLASMID LIBRARIES
2.10.1 RANDOM DNasel DIGESTION OF PLASMID DNA
Plasmids containing human and murine TP53 cDNA were randomly fragmented by 
digestion with DNasel as previously described (Holzmayer et a i, 1992). Each reaction 
sample consisted of 5pl DNA (5-10pg), 2.6yd lOx DNasel buffer and 4yd DNasel with 
the volume adjusted to 30pl. Reactions were incubated for 30min at 16°C and stopped by 
the addition of 4yd 500mM EDTA pH 8.0 to a final concentration of 5mM. Samples 
were purified using the Wizard DNA clean-up kit
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2.10.2 REPAIR OF FRAGMENTED DNA
The fragment termini were repaired with T4 DNA polymerase and Klenow fragment of 
DNA polymerase I. T4 DNA polymerase (10U) was added to 20yd DNasel digested 
DNA, 4|j,l IOx One-Phor-All PLUS buffer (Pharmacia) and 2yd lOmM dNTP with the 
volume adjusted to 40 pi. Enzyme reactions were incubated for 30min at 37°C. Klenow- 
Poll (10U) was added, left for a further 15min at the same temperature and samples were 
purified as before.
2.10.3 BLUNT-END LIGATION OF ADAPTORS
Adaptors were prepared by denaturation and annealling of oligomer sets: adaptorl - 
primers A and B; adaptor2 - primers C and D. lOOpg of each primer were mixed and the 
volume adjusted to lOOOpl with H20. Samples were incubated for lOmin at 90°C. After a 
further 30min incubation at 70°C, samples were allowed to cool down overnight to room 
temperature. DNA fragments (lOOng) were then ligated with an excess amount of each 
adaptors (500ng) using T4 DNA ligase (2U), 4yd 5x T4 DNA ligase buffer and 2yd 
lOmg/ml BSA with the volume adjusted to 20yd. Reactions were left at room 
temperature overnight and purified as before.
2.10.4 PCR AMPLIFICATION OF ADAPTOR LIGATIONS
Adaptor ligations (5yd aliquots) were amplified using the standard PCR protocol (section 
2.9.3) with primers A and D. Reaction conditions were as follows:
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94° C x 3min
94 C x lmin
56 C x lmin
72 C x lmin
25 cycles
Soak 4 C
PCR products were purified using the Wizard PCR preps kit.
2.10.5 RESTRICTION DIGEST OF VECTOR AND INSERTS
Both vector and inserts were sequentially digested using HindHI and Clal. The initial 
reaction consisted of 5pg DNA, 10pl lOx Reactl buffer (Gibco) and Clal (50U) with the 
volume adjusted to lOOpl. Samples were incubated for 4h at 37°C. After purification, 
50pl digested DNA was mixed with lOp.1 lOx React2 buffer and Hindlll (50U) with the 
volume adjusted to lOOp.1. Samples were purified as before.
2.10.6 LIGATION OF INSERTS TO RETROVIRAL VECTOR
Random fragment inserts were ligated to the retroviral vector plasmid, pLNCX, using T4 
DNA ligase. Reaction samples consisted of l-20ng insert, 50-100ng vector, 2pl 5x T4 
DNA ligase buffer, lp l lOmg/ml BSA and T4 DNA ligase (1U) with the volume adjusted 
to lOpl. Vector alone controls were included also.
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2.10.7 PCR AMPLIFICATION OF INSERT/VECTOR LIGATIONS
Insert/vector ligations (lpl aliquots) were amplified using the standard PCR protocol
with primers E and F. Reaction conditions were as follows:
94 C x 3min
94 C x lmin
60 C x lmin
72 C x lmin
25 cycles
Soak 4 C
2.10.8 GENERATION AND SCREENING OF LIBRARY CLONES 
Samples were transformed into competent bacteria and plasmid DNA prepared. Plasmid 
libraries were generated which comprised of 70,000 and 40,000 independent recombinant 
clones (>90% inserts as determined by Hindffl/Clal digestion and PCR amplification) 
from human and murine TP53 cDNA plasmids, respectively.
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2.11 IDENTIFICATION OF GSEs CONFERRING CISPLATIN RESISTANCE
2.11.1 LIBRARY TRANSDUCTION
PA317 cells were transfected with library DNA or insert-free pLNCX plasmid. Viral 
supernatant was collected from stable G418-resistant transfectants and used to infect 
A2780 cells.
2.11.2 CISPLATIN SELECTION
Stable A2780 infectants were seeded at 106/10cm plate, exposed to 10-20p.M cisplatin 
for 24h and left for 10-14 days (plating efficiency controls were included). Resistant 
colonies were picked and expanded.
2.11.3 ISOLATION OF PUTATIVE GSEs FROM GENOMIC DNA
Proviral inserts were recovered from the genomic DNA of cisplatin resistant A2780 
infectants by PCR with primers E and F. Reaction conditions were as follows:
94 C x 3min
94 C x lmin




2.11.4 SUBCLONING OF PUTATIVE GSEs AND IDENTIFICATION 
PCR products were re-cloned into the pLNCX vector plasmid maintaining original 
orientation of the insert. Subsequent to cloning, inserts were sequenced in both 
directions. Putative GSEs were compared against sequences present in the GenEMBL 
database using the GCG package. Sequence alignments of p53 GSEs versus human TP53 
cDNA are shown in Appendix I. Plasmids containing p53 GSEs were transfected into 




Two peptides were chemically synthesized and purified >95% by HPLC (Affiniti 
Research). PEP1-F corresponded to the 17 amino acid sequence predicted by the short 
sense-orientated element GSE1. A control peptide was created which comprised of the 




2.12.2 GEL MOBILITY SHIFT ASSAY
A 25pl reaction volume contained DNA binding buffer [20% glycerol, 25mM HEPES 
pH 7.6, 50mM KC1, 0.1% Triton X-100, ImM DTT and lmg/ml BSA] mixed with 
combinations of Baculovirus-expressed human p53 protein (Hansen et a l, 1996), 
radiolabelled oligonucleotide probe (comprised of the p53 DNA binding consensus site: 
El-Deiry et a l , 1992) and synthetic peptide. After incubation on ice for 30min, reaction 
products were processed by using native gel electrophoresis as indicated previously 
(Hupp et a l , 1992).
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3.1 INTRODUCTION
It has previously been demonstrated that expression of a dominant negative p53 mutant 
(codon 143, Val to Ala) in the human ovarian A2780 carcinoma cell line confers 
increased resistance to a variety of DNA damaging agents, including ionising radiation 
and cisplatin (Mcllwrath et al. , 1994; Vasey et al., in press). These mutant p53 
transfectants also lost the ability to undergo either ionising radiation or cisplatin induced 
G1 arrest and apoptosis (Mcllwrath et a l, 1994; Mcllwrath, Vasey and Brown,personal 
communication). Therefore, both of these phenotypes are dependent upon an intact p53- 
mediated DNA damage response pathway in this particular cell line.
A number of cisplatin resistant A2780 derivatives have been isolated by multiple 
step selection with increasing concentrations of cisplatin (Behrens et al. , 1987; Anthoney 
et al., 1996). This chapter investigates the role of p53 in the acquisition of cisplatin 
resistance in these cells. Various components of the p53-mediated DNA damage 
response pathway were studied in these cisplatin resistant cells. These include analysis of 
DNA damage (ionising radiation and cisplatin) induced cell cycle arrests and apoptosis, 
p53 protein accumulation and ability of p53 to transcriptionally activate certain target 
genes. All observations were compared with the sensitive parental A2780 cell line. 
Ionising radiation induced DNA damage provided a "direct" measure of p53 function in 
these cisplatin resistant cells without the problems associated with the determination of 
initial platinum-DNA adducts after cisplatin treatment
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3.2 REDUCED G1 ARREST AND APOPTOSIS
The effects of DNA damage on cell cycle progression may be analysed by flow cytometry 
in proliferating cells (Kastan et a l, 1991). Exponentially growing A2780 cells were 
treated with either ionising radiation or cisplatin and analysed 24h later by flow 
cytometry (Figure 5). After exposure to 2Gy 7-radiation, a decrease was observed in the 
proportion of A2780 cells which labelled positively after a 4h pulse of BrdUrd (Figure 
5). These cells have entered S-phase from the Gl-phase of the cell cycle and the 
observed decrease suggests an inhibition of DNA synthesis caused by a block at the Gl/S 
boundary (Kastan et al., 1991). Cells also accumulated in G2/M-phase of the cell cycle 
indicating a G2 arrest. It has been previously suggested that cisplatin does not induce a 
G1 arrest in mammalian cells (Demarcq et a l, 1992; Ormerod et a l, 1994). However, 
treatment of A2780 cells with 20pM/lh cisplatin induced both G1 and G2 arrests (Figure 
5). Specifically, a notable reduction was observed in the number of cells entering S-phase 
from G1 after cisplatin treatment (i.e. those cells with a 2N DNA content). In addition, 
there was a simultaneous increase in the number of S-phase cells with a 4N DNA 
content. These data are consistent with a decrease in the Gl/S transition, an increased 
period of transit time through S-phase and a subsequent G2 delay.
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Figure 5. DNA damage induced cell cycle arrests in A2780 cells.
Cell cycle analysis was accomplished by flow cytometric measurement of cells after bromodeoxyuridine 
(BrdUrd) incorporation during a 4h pulse and propidium iodide (PI) staining. Increase in FITC represents 
fluorescent labelling of an antibody against BrdUrd. At least 20,000 events were counted in each 
sample. Cells were treated with DNA damaging agents at indicated doses and left for 24h before analysis.
Time course studies were performed to further characterise these cell cycle 
arrests in A2780 cells and a cisplatin resistant derivative. The ionising radiation induced 
G1 arrest in the A2780 cell line appeared maximal 24h post treatment and had 
disappeared by 48h, indicating the reversible nature of the cell cycle arrest (Figure 6A). 
The degree of G1 arrest also increased with the dose of 7-radiation. The A2780/CP70 
cell line has previously been isolated from A2780 cells after two years selection with 
multiple exposures to cisplatin (Behrens et al., 1987). A2780/CP70 cells are 
approximately 5 fold more resistant to cisplatin than the parental line as determined by 
clonogenic assay (Brown et a l, 1993). These cisplatin resistant cells also show cross­
resistance to a number of DNA damaging agents including ionising radiation and 
doxorubicin (Brown et al., 1993; Vasey et al., in press).
The A2780/CP70 cells displayed a reduced G1 arrest in response to radiation 
treatment compared to the parental line (Figure 6A). These results are in agreement with 
previously published data and suggest that the p53-mediated DNA damage response 
pathway is dysfunctional in these cisplatin resistant cells (Brown et al., 1993). The G2 
arrest induced by ionising radiation was also dose-dependent and reversible in A2780 
cells with maximal accumulation of cells in G2/M-phase by 12h (Figure 6B). However, 
the A2780/CP70 cells showed no significant difference in ability to arrest in G2 than the 
parental line. A similar lack of correlation has been noted between radiation induced G2 
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Figure 6. Cell cycle arrests induced by ionising radiation.
The number of radiation treated cells with a 2N/4N DNA content and BrdUrd-i- (A) or 4N DNA content 
and BrdUrd- (B) was expressed as a percentage of untreated controls at each time point. Each point 
represents the mean of at least two independent determinations (>20,000 events counted). Open 
symbols and solid line, A2780; closed symbols and broken line, A2780/CP70. Cells were treated with y- 
radiation at doses of 2Gy (circles) or 4Gy (squares).
The symbols and bars refer to the mean and range of values, respectively.
A cisplatin dose-dependent and reversible reduction was observed in the 
percentage of BrdUrd positive A2780 cells with a 2N DNA content (Figure 7A). 
Maximal inhibition of DNA synthesis in A2780 cells occurred 24h post treatment. 
Treatment of A2780/CP70 cells with cisplatin at either 20 pM or 40pM for lh  did not 
induce a decrease in the percentage of cells entering S-phase. This indicates that the 
A2780/CP70 cells have an abrogated G1 arrest in response to cisplatin, although intact in 
the parental line. These results again suggest that the A2780/CP70 cells have a defective 
p53-mediated DNA damage response pathway. It has been proposed that the G2 arrest is 
necessary for cisplatin to mediate its cytotoxic effects (Eastman, 1990). The A2780 cells 
also showed a marked G2 arrest after exposure to cisplatin which was reversible and 
occurred maximally 24h post treatment (Figure 7B). On the other hand, the A2780/CP70 
cells demonstrated little or no G2 arrest after cisplatin treatment. These observed 
differences between the ionising radiation and cisplatin induced G2 arrests will be 
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Figure 7. Cell cycle arrests induced by cisplatin.
The number of cisplatin treated cells with a 2N DNA content and BrdUrd+ (A) or 4N DNA content and 
BrdUrd- (B) was expressed as a percentage of untreated controls at each time point. Each point 
represents the mean of at least two independent determinations (>20,000 events counted). Open 
symbols and solid line, A2780; closed symbols and broken line, A2780/CP70. Cells were treated with 
cisplatin for lh at doses of lOpM (circles), 20pM (squares) or 40pM (triangles).
j The symbols and bars refer to the mean and range of values, respectively.
The multi-agent resistance phenotype observed in A2780/CP70 cells may be due 
to an inability to undergo DNA damage induced apoptosis (Wyllie, 1993; Enoch and 
Norbury, 1995). DNA strand breaks generated during apoptosis can be detected by end- 
labelling of the DNA with biotin-dUTP using terminal transferase and detection of 
labelled cells with fluorescein-avidin (Gorczyca et a l , 1993b). This technique is referred 
to as TUNEL. The proportion of cells staining positively by TUNEL may be quantified 
using flow cytometry. Treatment of A2780 cells with either 2Gy y-radiation or 40[iM/lh 
cisplatin induced a high rate of apoptosis 72h later (Figure 8). Indeed, time course 
studies have shown this to be the time point where maximal apoptosis occurs in response 
to DNA damage (Mcllwrath, personal communication). However, the A2780/CP70 line 
displayed a reduced level of apoptosis using similar treatments compared to the parental 
cells. It has previously been shown that A2780/CP70 cells form 2 fold less platinum- 
DNA adducts than the parental line when treated at equivalent cisplatin exposures 
CJohnson et al., 1994). At cisplatin exposures which induce comparable levels of initial 
DNA damage, the resistant cells still showed markedly reduced levels of apoptosis (data 
not shown). These results further support the notion of a dysfunctional p53-mediated 
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Figure 8. Apoptosis induced by ionising radiation and cisplatin.
Flow cytometric analysis of DNA strand breaks. Increase in FITC represents end-labelling of the DNA 
with biotin-dUTP using terminal transferase and detection of labelled cells with fluorescein-avidin. At 
least 15,000 events were counted in each sample. Cells were treated with DNA damaging agents 
at indicated doses and left for 72h before analysis. The apparent subpopulation of cells with >4N DNA 
content represented less than 5% of total cell number and may be an artifact of the TUNEL procedure.
3.3 INCREASED ACCUMULATION OF p53 PROTEIN
It has previously been shown that A2780/CP70 cells have elevated constitutive levels of 
p53 protein compared to the parental A2780 cells, but that both lines express wild-type 
TP53 mRNA (Brown et al. , 1993). The results presented in the previous section indicate 
that the DNA damage response pathway controlled by p53 is abrogated in the cisplatin 
resistant A2780/CP70 cells. Therefore, the following work attempts to elucidate the 
mechanism of p53 dysfunction in these cells. It also investigates the kinetics of p53 
accumulation by ionising radiation and cisplatin. The data presented in Figure 9 was 
obtained from Dr. Robert Brown, CRC Department of Medical Oncology. This figure 
illustrates the time course of p53 protein accumulation in A2780 and A2780/CP70 cells 
after treatment with either ionising radiation or cisplatin. Exposure of A2780 cells to 2Gy 
y-radiation induced increased cellular accumulation of p53 protein (Figure 9A and C). 
The p53 protein levels maximally increased in the A2780 cells by 4h and returned to 
control amounts by 48h. These kinetics of induction by ionising radiation are similar to 
those observed in other wild-type p53 expressing cells (Kastan et a l, 1991). The 
A2780/CP70 cells showed increased constitutive levels of p53, but also an increase in 
p53 accumulation after irradiation. However, the p53 protein level was still increased in 
the A2780/CP70 line at 48h after treatment. Elevated accumulation of p53 protein has 
been detected in the A2780/CP70 line as late as 96h after treatment (data not shown).
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Figure 9. Time course of p53 protein accum ulation in response to DNA damage.
The following data was obtained from  Dr. R. Brown. CRC Department o f  M edical Oncology. Glasgow. 
(A. B) Western blot analysis o f p53 protein levels in cell extracts using an anti-p53 MAh (clone DO-1). 
The correct size o f  p53 protein (53kD a) was determined by using a 2 9 .5 -2 14kDa protein ladder (Gibco 
BRL). (C . D) ELISA analysis o f  p53 protein levels in cell extracts using an anti-p53 M Ab (clone DO- 
1). V alues shown me the O.D.450nm o f bound com plexes visualised with tetrametliylbenzidine ( lOOpg of 
total protein cell extract). The ELISA assays were linear over this range. Values represent the mean of 
16 independent determ inations and error bars represent the SDM . C ells were treated with either y- 
radiation (A. C) or cisplatin (B. D) at doses o f 2Gy or lp M /lh . respectively. Extracts were prepared 
after treatment at time points indicated.
1 2 3 4 5 6 7
A 2780 A2780/CP70
Maximal accumulation of p53 protein in the A2780 cells occurred 24h after 
treatment with lpM /lh cisplatin (Figure 9B and D). The significance of this delayed 
accumulation of p53 protein in response to cisplatin is discussed in Chapter 5. Again, 
increased accumulation of p53 protein was observed in the A2780/CP70 cells compared 
to the parental line. However, the increased accumulation of p53 protein in A2780/CP70 
cells after either ionising radiation or cisplatin treatment does not correlate with increased 
p53 activity (as determined by DNA damage induced G1 arrest and apoptosis), even 
though these cells express wild-type p53.
Immunocytochemical analysis revealed information on the subcellular localisation 
of p53 protein in A2780 and A2780/CP70 cells (Figures 10 and 11). These studies 
employed the use of an isotype specific antibody (IgG2b) in place of the primary antibody 
against p53 for staining control purposes. Increased levels of cytoplasmic p53 protein are 
often associated with dysfunctional p53 (Bartek et a l, 1990). However, the elevated p53 
protein observed in the A2780/CP70 line was nuclearly localised as determined by 
confocal microscopy (Figure 10). Following DNA damage, p53 can only function to 
arrest the cell cycle if the protein is located in the nucleus (Shaulsky et a l , 1991). The 
A2780 and A2780/CP70 cells displayed nuclear accumulation of p53 protein in response 
to either 2Gy 7-radiation or lpM/lh cisplatin (Figures 10 and 11), which is consistent 
with both lines expressing wild-type p53. It is of interest to note that the accumulated 
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Figure 10. Nuclear accumulation o f  p53 protein - ionising radiation.
Immunocytochemical analysis o f  p53 protein expression was accomplished by confocal microscopy using an 
anti-p53 MAb (clone P A b l22). An isotype specific antibody ( I^G2b> vv'as used in place o f the primary 
antibody for staining control purposes. Cells were treated with 2G y ’/-radiation and fixed at the time points 
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Figure 11. Nuclear accumulation o f p53 protein - cisplatin.
Immunocytochemical analysis o f  p53 protein expression w as accom plished by confocal m icroscopy using 
an aiiti-p53 M Ab (clone P A b l22 ). An isotype specific antibody (IgG-,b ) w as used in place o f  the primary 
antibody for staining control purposes. C ells w ere treated with l |iM  cisp latin /lh  and fixed at the time 
points indicated. Each image w as divided into signals derived from  either FITC (left) or PI (right) staining.
Flow cytometry was used to determine the percentage of the total cell population 
which stained p53 positive and provide information on the cell cycle related expression of 
p53 protein in response to ionising radiation and cisplatin (Figures 12 and 13). Figure 12 
illustrates that a small proportion of A2780 cells (4%) were p53 positive compared to 
A2780/CP70 cells (37%). The percent of cells with detectable p53 increased maximally 
in the A2780 line 4h after irradiation and had mostly returned to control levels by 24h. 
The majority of A2780/CP70 cells (83%) stained positively for p53 4h after irradiation 
and maintained this increased level at 24h. Maximal accumulation of A2780 cells which 
were p53 positive was observed 24h after cisplatin treatment (Figure 13). A sustained 
cisplatin induced accumulation of A2780/CP70 cells staining positively for p53 was 
detected (60% by 48h). These results are in general agreement with the Western blot and 
ELISA studies described in Figure 9. There were no apparent differences between A2780 
and A2780/CP70 cells regarding the cell cycle related expression of p53 protein in 
response to either ionising radiation or cisplatin (Figures 12 and 13). These results are 
comparable with a previous study showing UV induced accumulation of p53 protein in 
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Figure 12. Cell cycle related expression of p53 protein - ionising radiation
Immunocytochemical analysis of p53 protein expression was accomplished by flow cytometry using an 
anti-p53 MAb (clone PAbl22). An isotype specific antibody (IgG2b) was used in place of the primary 
antibody for staining control purposes. Cells were treated with 2Gy y-radiation and fixed at the time 
points indicated. Percentages refer to the number of cells within the total population which were p53+ 
as determined by an increase in FITC staining above control levels. Each value represents the mean of 























Figure 13. Cell cycle related expression of p53 protein - cisplatin.
Immunocytochemical analysis of p53 protein expression was accomplished by flow cytometry using an 
anti-p53 MAb (clone PAbl22). An isotype specific antibody (IgG2b) was used in place of the primary 
antibody for staining control purposes. Cells were treated with lpM cisplatin/lh and fixed at the time 
points indicated. Percentages refer to the number of cells within the total population which were p53+ 
as determined by an increase in FITC staining above control levels. Each value represents the mean of 
at least two independent determinations (>20,000 events counted).
3.4 LOSS OF p53 TRANSCRIPTIONAL ACTIVITY
If the reduced DNA damage induced G1 arrest and apoptosis observed in the cisplatin 
resistant A2780/CP70 cells was due to a defective p53 pathway, a reasonable prediction 
would be that these cells also had reduced p53 transcriptional activity. Transcription of 
the CIP1 gene is partially regulated by p53 and is necessary for radiation induced G1 
arrest (El-Deiry et a l, 1994). Levels of CIP1 mRNA in both A2780 and A2780/CP70 
cells were quantified by hybridisation of a Northern blot with a CIP1 cDNA probe 
(Figure 14). This data was obtained in collaboration with Dr. Angela Edlin, CRC 
Department of Medical Oncology. The A2780/CP70 cells contained 3-4 fold reduced 
CIP1 mRNA compared to the parental A2780 cells. Treatment of A2780 cells with either 
2Gy y-radiation or lpM /lh cisplatin induced CIP1 mRNA (Figure 14A and B). Based on 
densitometric scanning of relative hybridisation signals, ionising radiation treatment 
induced a 4.5 fold increase in CIP1 mRNA by 4h. Cisplatin treatment showed little CIP1 
induction at 4h (1.4 fold), but did increase CIP1 mRNA by 4 fold at 24h. These results 
are consistent with the delayed induction of p53 protein levels by cisplatin in the A2780 
cells (Figures 9B and D, 11 and 13). Ionising radiation induced CIP1 mRNA 2 fold at 4h 
in the A2780/CP70 cells, however this is markedly reduced compared to the induced 
CIP1 mRNA levels in the A2780 cells. In addition, little or no induction of CIP1 mRNA 
by lpM /lh cisplatin was observed in the A2780/CP70 cells. The reduced transcription of 
the CIP1 gene in response to either ionising radiation or cisplatin is again consistent with 
abrogated p53 function in the A2780/CP70 line.
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Figure 14. Expression o f CIP1 mRNA in cisplatin resistant cells.
Northern blot o f total RNA was hybridised witli CIP1 and GAPDH probes. RNA  was extracted from cells at 
the indicated time points after treatment (+) with either (A) 2Gv y-radiation or (B) lpM  cisplatin/1 h . 
Untreated control (-) samples tire also shown. (C) Constitutive CIP1 mRNA levels within A2780/M C P lines. 
Lane L A2780: lane 2. A 2780/CP70: lanes 3-11. A 2780/M CP1-9. Correct size o f transcripts was confirmed 
by comparison with size markers. The data fo r  A and B was obtained in collaboration with Dr. Angela  
Ed I in. CRC Department o f  M edical Oncology.
Nine independent cisplatin resistant A2780 lines (MCP1-9) have recently been 
isolated by repeated exposure to increasing concentrations of cisplatin up to a final 
concentration of 15pM (Anthoney et a l, 1996). Characterisation of these cell lines has 
been performed mainly by Dr. Alan Anthoney, CRC Department of Medical Oncology. 
All of these lines have been shown to be stably resistant (1.3-4.7 fold) to cisplatin 
compared to the parental A2780 line (Table 1). The majority of the multiply selected 
cisplatin resistant lines showed reduced CIP1 mRNA levels (Figure 14C and Table 1). 
These resistant lines also appeared deficient in DNA damage induced G1 arrest and 
apoptosis responses which is consistent with loss of p53 function being a general 
phenomenon in acquired cisplatin resistance (Table 1). Western blot analysis revealed 
that the resistant lines contained varying constitutive levels of p53 protein. Whereas some 
lines (A2780/MCP1, A2780/MCP3 and A2780/MCP5) exhibited elevated levels of p53 
protein compared to the parental A2780 line, many had no detectable difference, and 
none had the enhanced levels to the extent observed in the A2780/CP70 line.
The next stage of the study was to determine the nature of the p53 dysfunction in 
A2780/CP70 cells. It has been proposed that mdm2 overexpression may constitute an 
alternative pathway to mutational inactivation of p53 (Meltzer, 1994). Indeed, mdm2 
protein has been shown to complex with p53 and inhibit its transcriptional activation 
ability (Momand et al., 1992; Oliner et a l, 1993). However, there was no evidence of 
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Figure 15. Constitutive levels o f MDM2 mRNA and protein.
(A) Northern blot of total RNA was hybridised with MDM2 tuid GAPDH probes. RNA was extracted from 
untreated exponentially growing cells. Correct size of transcripts was confirmed by comparison with 
size markers. (B ) Immunocytochemical analysis of mdm2 protein expression was accomplished by 
confocal microscopy using an anti-mdm2 MAb (clone IF2). An isotype specific antibody (IgG,b) was 
used in place of the primary antibody for staining control purposes. Each image was divided into 
signals derived from either FITC (left) or PI (right) staining.
Attempts at quantification of mdm2 protein levels in either cell line by Western 
blot analysis proved unsuccessful. The MDM2 gene is itself a transcriptional target of 
p53 (Barak et a l, 1993; Perry et al., 1993). Reduced levels of MDM2 mRNA (4 fold) 
were observed in the A2780/CP70 cells compared to the parental line (Figure 15A). 
These results add weight to the assertion that the p53 protein in the A2780/CP70 cells, 
despite having wild-type TP53 sequence, is functionally inactive for transcriptional 
activation. Considering that transcription of both the CIP1 and MDM2 genes was 
reduced in the A2780/CP70 cells, the defect in the p53-mediated DNA damage response 
pathway was assumed not to lie downstream of p53.
3.5 PATTERN OF p53 PROTEIN ISOFORMS
It has been suggested that phosphorylation of p53 protein may be one of the signals 
leading from DNA damage to p53 activation (Milne et al., 1995). Therefore, a defect in 
phosphorylation of p53 would be a likely candidate for the p53 dysfunction observed in 
the cisplatin resistant cells. Using 2D-PAGE, charged isoforms of p53 protein can be 
identified (Merrick et al., 1995). Such isoforms have been shown to represent specific 
phosphorylated forms of p53 protein (Merrick et a l, 1995). Twelve major isoforms of 
p53 protein were consistently observed in both A2780 and A2780/CP70 cells having 
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Figure 16. Spectrum of p53 protein isoforms revealed by 2D-PAGE.
The p53 protein isoform s were separated by 2D-PAG E. transferred by Western blotting onto an 
Im m obilin-P membrane and detected im m unologically using an anti-p53 MAb (clone D O - l). Enhanced  
cliem ilum inescence and autoradiography allowed the visualisation o f protein-antibody com plexes. 
Image capture and profile analysis was achieved using PDQuest software. The above data w as com piled  
from a single experim ent, although sim ilar results w ere observed in two other independent experim ents. 
A: images: B: profiles. A 2780  (I-OGy) and (IlI-4Gy 6h): A 2780/C P70 (II-OGy) and (IV-4G y 4h). pi 
refers to the isoelectric point o f  the protein isoforms detected. The 2D-PAGE was carried out by Lynn 
M cGarry , Bea!son Institute.
The number and charge of p53 isoforms observed are comparable with those 
previously characterised by others (Merrick et al., 1995). The most cathodic isoform (pi 
~ 6.7) is assumed to represent the unphosphorylated backbone of p53. Profile analysis 
revealed no gross differences in the pattern of p53 isoforms between both A2780 and 
A2780/CP70 cells either on a constitutive basis or after exposure to ionising radiation. 
Although there may be very specific alterations in the pattern of p53 isoforms, the data 
does not provide any clear evidence for a defect in the phosphorylation of the p53 
protein in A2780/CP70 cells.
3.6 UNSCHEDULED CYCLIN PROTEIN EXPRESSION
The following work presents data on a potentially interesting abnormality found in the 
cisplatin resistant A2780/CP70 cells and does not have any direct relevance to the 
primary aim of Chapter 3 (i.e. to investigate the role of p53 in acquired cisplatin 
resistance). Cyclins are key components of the cell cycle machinery (Baserga, 1990; 
Norbury and Nurse, 1992). They are expressed selectively in different phases of the cell 
cycle and function by activating one of several CDKs, each of which phosphorylates a 
distinct group of proteins that in turn causes advancement of the cell through a particular 
stage of the cell cycle. Cyclin B1 (a G2 cyclin) is required for entrance of the cell into 
mitosis and its expression is confined mainly to the G2/M-phase cell population. Cyclin E 
(a G1 cyclin) controls progress into S-phase and maximal expression of this protein 
occurs during the Gl-S transition.
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Unscheduled expression of cyclin B1 and E proteins have been observed in a 
variety of leukaemic and solid tumour cell lines (Gong et al. , 1994). Such ectopic 
expression of cyclin proteins may indicate defective cell cycle regulatory mechanisms. 
The cell cycle related expression of both cyclin B1 and E proteins was examined in 
A2780 and A2780/CP70 cells. A2780 cells exhibited a normal pattern of cyclin B1 
protein expression, i.e. peaking during G2/M-phase (Figure 17). However, a significant 
subpopulation of A2780/CP70 cells (11%) with a 2N DNA content were cyclin B1 
positive compared to the parental line (1%). No evidence of aberrant expression of cyclin 
E protein was observed in either A2780 or A2780/CP70 cells. In both cell lines, cyclin E 
protein was maximally expressed in late G1 cells and its content progressively declined 
during S-phase. Ectopic expression of cyclin B1 was only observed in two cisplatin 
resistant lines, one of which includes A2780/CP70 (Figure 17B and Table 1). This 
suggests that unscheduled expression of cyclin B1 may not be a general phenomenon in 
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Figure 17. Cell cycle related expression of cyclin B1 and E protein.
(A) Immunocytochemical analysis of cyclin proiein expression by flow cytometry using anti-cyclin B1 
(clone GNS-1) and ami-cyclin E (clone HE12) MAbs. An isotype specific antibody (IgGj) was used in 
place of the primary antibody for staining control purposes. Percentages refer to the number of cells 
within the total population which were cyclin B1 or E positive as determined by an increase in FITC 
staining above control levels. Each value represents the mean of at least two independent 
determinations (>20,000 events counted). (B) Summary of cyclin B1 and E results. The number of cells 
with either 2N or 4N DNA which stained positive for cyclin expression was expressed as a percentage 
of the total number of cells with the same DNA content.
3.7 SUMMARY
Evidence has been presented for a defect in the p53-mediated DNA damage response 
pathway in cisplatin resistant derivatives of A2780 cells as determined by reduced DNA 
damage induced G1 arrest, apoptosis and transcription of certain target genes. The basis 
of the p53 dysfunction in one of these resistant cell lines (A2780/CP70) does not appear 
to be due to overexpression of mdm2 protein, differences in the cell cycle related 
expression of p53 protein or gross changes in the pattern of p53 isoforms. In addition, 
previous sequencing of the entire TP53 cDNA from this line revealed no mutations 
(Brown et a l , 1993). The proposed mechanism of p53 dysfunction in these cisplatin 
resistant cells is discussed in Chapter 5.
A possible limitation of this work was the reliance on indirect measures of p53 
function such as transcription activation of endogenous p53 target genes. It is 
conceivable these genes are regulated by other factors within the cell apart from p53. In 
particular, expression of CIP1 has been shown to be regulated by p53-independent 
mechanisms (Michieli et al., 1994; Macleod et a l, 1995). However, reporter constructs 
using specific p53-responsive promoters would allow direct assessment of the 
transcriptional activation-dependent functions of p53 only. Ionising radiation was useful 
in evaluating the p53 response, where the degree of platinum-DNA adduct formation 
after cisplatin treatment was an unknown entity (as in A2780/MCP1-9 lines).
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4.1 INTRODUCTION
As mentioned in the previous chapter, transfection of a dominant negative p53 mutant 
(codon 143, Val to Ala) into the A2780 cell line confers increased resistance to cisplatin 
(Vasey et a l, in press). In the present study, libraries of recombinant retroviruses, 
expressing random fragments of human or murine TP53 cDNA plasmids, were 
introduced into A2780 cells and the resulting clones selected on the basis of cisplatin 
resistance. It was predicted that cisplatin selection would enrich for GSEs which could 
abrogate the endogenous p53-mediated DNA damage response pathway. The primary 
aim was to identify small molecules (dominant negative peptides or antisense RNA) 
derived from p53 which allow modification of the p53 response to genotoxic stress.
4.2 RANDOM FRAGMENT p53 EXPRESSION LIBRARIES
The construction and utilisation of the random fragment p53 expression libraries is 
outlined as follows. Plasmids containing human and murine TP53 cDNA were randomly 
digested with DNasel. Each fragment was ligated to asymmetrical adaptors which 
provide translational initiation and termination sites and allow for oriented cloning. 
Following PCR amplification using primers derived from the adaptor sequences, these 
fragments were inserted between Hindin/Clal sites within the pLNCX retroviral 
expression vector plasmid. Libraries of recombinant plasmid clones were generated and 
transfected into an amphotropic virus packaging cell line. Viral supernatants (containing 
the p53 recombinant retroviruses) were collected and used to infect A2780 cells. Figure 
4 displays the structure of a hypothetical integrated LNCX provirus containing a 
fragment of TP53 cDNA.
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A detailed description regarding the generation of the random fragment p53 
plasmid libraries can be found in Chapter 2 (section 2.10). The initial step in this process 
was the random fragmentation of human and murine TP53 cDNA plasmids. Both 
plasmids were partially digested with serial dilutions of DNasel (Figure 18A). Fragments 
between 50 and 500bp were isolated (Figure 18A, lane 4) and rendered blunt-ended as 
previously described (Holzmayer et a l, 1992). Synthetic adaptors were ligated to these 
fragments using T4 DNA ligase and subsequently amplified by PCR using primers 
derived from the adaptor sequences (Figure 18B, lanes 1-4). Self-ligated adaptors were 
removed by a purification step (Figure 18B, lanes 5-8). Amplified random fragments 
were digested with HindlTI/Clal and inserted into the corresponding cloning site within 
the pLNCX vector plasmid using T4 DNA ligase. Integration of these random fragments 
into the vector was determined by PCR amplification using primers spanning the cloning 
site (Figure 18C).
PCR amplification of vector alone ligations produced a DNA fragment of 165bp 
as predicted (Figure 18C, lane 9; Miller and Rosman, 1989). Larger DNA fragments 
(>200bp) were also observed in PCR products obtained from insert/vector ligations 
(Figure 18C, lanes 1-8). This indicates that the random fragments had successfully 
integrated into the vector cloning site. The vector alone PCR product was undetectable 
in certain ligations, particularly those reactions with a high insert to vector ratio (Figure 
18C, lanes 7-8). These ligations were predicted to have negligible amounts of non­
integrated vector and therefore ideal for the generation of recombinant plasmid libraries.
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Competent bacterial cells were transformed with DNA from such ligations and selected 
on the basis of ampicillin resistance.
Plasmid DNA was isolated from pools of transformed bacteria (>1000 clones 
each). Random fragment inserts were amplified from these plasmid libraries by PCR 
using primers spanning the cloning site (Figure 18D). The majority of the resulting PCR 
products ranged in size from 250 to 600bp (Figure 18D, lanes 1-10). No discrete PCR 
products were observed indicating that no particular sequences were over-represented 
within the plasmid libraries. In total, libraries of 70,000 and 40,000 plasmid clones were 
constructed which contained 50-500bp fragments from human and murine TP53 cDNA 
plasmids, respectively (Table 2). Over 90% of the plasmid clones within both libraries 
were predicted to contain recombinant inserts (Table 2 and Figure 19).
Table 2. Random fragment p53 plasmid libraries.
Species origin Number of clones3 Recombinants^
Human 70,000 >90%
Murine 40,000 >90%
a. The number of plasmid clones was calculated by plating small aliquots of the bacterial cell cultures 
and counting the number of transformed colonies, b. Plasmid DNA was extracted hum >50 independent 
bacterial cell clones. The percentage of recombinants within these plasmid clones was determined by 














Figure 18. Construction o f random fragment p53 plasmid libraries.
(A) Random fragmentation o f human TP53 cD N A  plasm id. Plasmid DNA  (10gg) was incubated with 
serial dilutions o f D N asel for 30m in. Lanes 1-6. 10 fold serial d ilutions o f enzym e with initial reaction 
containing 4U : lane 7. no enzym e added. (B) PCR am plification o f  adaptor ligations. Synthetic adaptors 
(500ng) were ligated to random D NA  fragments (lOOng) using T4 D N A  ligase (2U) and subsequently 
amplified by PCR using primers derived from the adaptor sequences. PCR products were purified using 
the Wizard PCR preps kit. Lane 1-4. PCR products from adaptor ligations before purification; lanes 5-8. 
PCR products from adaptor ligations after purification.
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(C) PCR am plification of insert/vector ligations. Random DNA fragments were digested with 
H indlll/C lal and inserted into the corresponding cloning site within the pLNCX vector plasm id using 
T4 D NA  ligase (1 U ) Ligation reactions were subsequently amplified by PCR using primers spanning 
the cloning site. Lanes 1 and 5. ln g  insert: lanes 2 and 6. 5ng insert: lanes 3 and 7. lOng insert, lanes 4 
and 8: 20ng insert: lane 9: no insert. Lanes 1-4. lOOg vector; lanes 5-9. 50ng vector. (D) PCR 
am plification o f random fragment po3 plasmid libraries. Plasmid D NA  was isolated from pools of 
bacteria (> 1000  clones each) transformed with certain insert/vector ligations and subsequently 
am plified by PCR using primers spanning the cloning site. Lanes 1-10. plasmid from different pools of 
transformed bacteria: lane 11. vector alone plasmid.
Figure 19. Screening o f recombinant plasmid library clones.
PCR am plification o f individual plasmid clones from recombinant libraries using primers spanning the 
cloning site. PCR products from all of these plasnnd clones contained DNA fragments of >165bp  
(which is obtained using the vector alone plasm id), indicating the presence o f recombinant inserts. 
Limes 1-12. individual plasmid clones; lane 13. vector alone plasmid.
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Figure 20. Cisplatin selection of A2780 infectants.
PCR am plification o f proviral inserts from genom ic DNA using primers spanning the cloning site. 
Genomic D NA  was isolated from A 2780 infectants before (limes 1-2) and after (lanes 3-5) cisplatin 
selection. Lanes 1 and 3-4. murine p53 library; lanes 2 and 5. human p53 library.
Both plasmid libraries were transfected into the murine amphotropic virus 
packaging PA317 cell line (Miller and Buttimore, 1986). Transfection efficiencies were in 
the range 100 to 500 CFU/106 viable cells/pg vector. A total of 2,500 stable PA317 
transfectants were isolated from each library. Retroviral particles derived from these 
transfectants formed the basis of the random fragment p53 expression libraries. A2780 
cells were infected with either the human or murine p53 recombinant retroviruses. Viral 
titres ranged from 50 to 300 CFU/106 viable cells/ml. A total of 10,000 stable A2780 
infectants were isolated from each library. Most of the infected clones were expected to 
contain only one copy of the integrated provirus (Coffin, 1996).
4.3 ISOLATION OF p53 GSEs WHICH CONFER RESISTANCE TO 
CISPLATIN
Pools (>1000 clones) of stable A2780 infectants (p53 libraries or vector alone) were 
subjected to cisplatin selection. It has been shown that cisplatin resistant mutants can be 
isolated from A2780 cells using a single step selection protocol (McLaughlin et al., 
1991). Treatment of vector alone A2780 infectants with 12.5p,M cisplatin for 24h gave a 
frequency of 2 x 10'5 surviving colonies/viable cell. Pools of A2780 cells infected with 
differing populations of either human or murine p53 recombinant retroviruses were 
selected at the same drug exposure. Frequencies of surviving colonies/viable cell were 
observed in the range 7 to 56 x 10'5, representing a 4 to 29 fold increase in the number of 
cisplatin resistant colonies induced by the p53 recombinant libraries.
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Genomic DNA was isolated from A2780 infectants before and after cisplatin 
selection. Integrated proviral elements were amplified by PCR using primers spanning the 
cloning site (Figure 20). The PCR products from A2780 infectants before cisplatin 
selection showed a continuous distribution in size range from 250 to 600bp (Figure 20, 
lanes 1-2). This indicates that representation of the random fragments was maintained 
after retroviral transduction. However, an enrichment for specific DNA fragments was 
observed after cisplatin selection of the A2780 infectants (Figure 20, lanes 3-5).
These discrete PCR-amplified fragments from cisplatin selected A2780 infectants 
were recloned into the pLNCX vector plasmid in the same position and orientation as the 
primary construct. Sequence analysis revealed that subcloned inserts were derived from 
TP53 cDNA (sequence alignments are shown in Appendix I). It is worth noting that less 
than 20% of the original plasmid libraries contained p53 inserts (the remaining inserts 
being from the vector constructs). These observations show that cisplatin selection of 
A2780 cells infected with either library enriched for p53-derived GSEs.
The orientation and position of the six p53-derived GSEs isolated are shown in 
Table 3 and Figure 21. The four antisense-oriented GSEs were clustered around the 
central region of the TP53 gene (nucleotides 361-680). The sense-oriented element 
GSE1 was predicted to encode a short 17 amino acid peptide containing 11 amino acids 
of the human p53 protein (300-310) plus amino acids from the outlying adaptor 
sequences. GSE1 is derived from an uncharacterised "linker" region found between the 
sequence-specific DNA binding and oligomerisation domains and is adjacent to a cyclin 
dependent kinase site (Bischoff et a l , 1990).
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Table 3. Position and orientation o f p53-derived GSEs.
GSE Origin Orientation Position Size
N A N A
GSE1 Human Sense 898-930 300-310 33 11
GSE2 Human Antisense 362-463 102
GSE3 Murine Antisense 560-680 121
GSE4 Human Antisense 487-555 69
GSE5 Murine Antisense 558-610 53
GSE6* Murine Sense 751-837 251-279 87 29
Sequence comparisons were made relative to human TP53 cD N A  (Appendix I). N=nucleotides. 
A=am ino acids. *This putative GSE was enriched after cisplatin selection but was not reintroduced into 
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Figure 21. Schematic representation of human p53 showing position of GSEs.
Sense and antisense-oriented elem ents are shown by forward and reverse arrows, respectively. Som e of 
the known functional sites within human p53 are indicated including the transactivation, sequence- 
specific D N A  binding and oligomerisation domains (for a more com plete description see reviews: 
Deppert, 1994; Harris, 1996). CDK=cyclin-dependent kinase site. Conserved regions of hom ology I-V 
shown as hatched boxes and C-terminal negative regulatory domain denoted by a solid box.
The predicted peptide sequence from the putative element GSE6 (amino acids 
251-279) was localised to a portion of the sequence-specific DNA binding domain (Cho 
et a l, 1994). Interestingly, most of the GSEs derived from murine TP53 cDNA 
converged upon areas which contain highly conserved regions of homology (II-V) 
(Soussi et a l , 1990). This might be expected considering the GSEs of murine origin were 
selected in a human cell background.
The ability of the molecularly isolated GSE clones to confer cisplatin resistance 
was evaluated by both colony formation and growth inhibition assays. A2780 cells were 
independently transfected with individual plasmid clones (GSE1-5) and pools of 
transfectant colonies isolated (>50 colonies for each GSE). Table 4 shows the relative 
levels of resistance to cisplatin for A2780 GSE transfectants. GSE-carrying cells were 
more resistant than cells with insert-free provirus (1.2-2.9 fold by clonogenic assay). 
These levels are comparable with the 2-3 fold increase in cisplatin resistance observed by 
clonogenic assay when a dominant negative p53 mutant (codon 143, Val to Ala) is 
introduced into the same cell line (Vasey et a l, in press). The higher fold resistance 
measurements obtained using the MTT cell viability assay (1.5-8.2 fold) may reflect 
cytostatic effects on cell growth induced by cisplatin. These results demonstrate that the 
isolated p53 GSEs conferred cisplatin resistance in A2780 cells. It is important to note 
that these phenotypic effects were observed with mass populations of transfectant cells, 
thus obviating the problems associated with clonal variability (although possibly reducing 
the potential fold resistance measurements which may have been observed in clonal 
isolates).
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Table 4. Characteristics of A2780 GSE transfectants.
GSE Plating efficiency^ Fold resistance Relative p53 protein^
Clonogenic assay*3 M i l  assay0 level
VECTOR 0.14 1.0 1.0 1.0
GSE1 0.14 2.0 (0.1) 4.1 (0.7) 1.5
GSE2 0.17 1.2 (0.3) 1.5 (0.2) 0.8
GSE3 0.13 2.9 (0.6) 8.2 (0.9) 0.5
GSE4 0.15 1.9 (0.4) 3.2 (0.9) 0.4
GSE5 0.14 2.2 (0.6) 4.5 (0.2) 0.4
The figures in parenthesis refer to the SEM. Calculation of resistance and p53 protein levels were made 
relative to vector alone A2780 transfectants. a. Plating efficiencies were calculated from the fraction of 
seeded cells which formed colonies. There were no apparent differences between vector alone controls 
and GSE transfected populations with respect to population doubling times, b. Calculated from the 
surviving fraction of cells after exposure to 20|iM cisplatin for lh. Each value is the mean of four 
independent determinations, c. Calculated using IC5 0  values obtained from at least two experiments, d. 
Relative level of p53 protein as detected by Western blot analysis and standardised with vinculin 
expression. Each value is the mean of at least two determinations.
4.4 ABROGATION OF p53-MEDIATED DNA DAMAGE RESPONSE 
PATHWAY
The next step was to establish which mechanism the isolated p53 GSEs acted through. 
Ultimately, the inhibitory activity of antisense RNA is mediated by downregulation of 
protein expression (Takayama and Inouye, 1990; Denhardt, 1992). Western blot analysis 
revealed that the antisense GSE transfectants (GSE3-5) contained lower levels of p53 





Figure 22. Levels of p53 protein in A2780 GSE transfectants.
W estern hlot analysis o f p53 protein in cells transfected with G SEs by using an anti-p53 MAb (clone
D O -l). Control for loading was provided by using an anti-vinculin  MAb (clone V IN -1 1-5). S izes were 
determ ined by using a 2 9 .5 -2 14kDa protein ladder (G ibco BRL). Lime 1. A 2780 pLNCX transfectants:
lane 2. A 2780  GSE1 transfectants: lane 3-5. A 2780 G SE3-5 transfectants.
These results suggest that the induction of cisplatin resistance in A2780 cells by 
antisense GSEs was due to loss of p53 function through reduced levels of the protein. It 
is worth noting that reintroduction of GSE2 did not significantly affect cisplatin 
resistance or the level of p53 protein in A2780 cells (Table 4). This may represent either 
inadequate expression in transfectant cells or the biological ineffectiveness of this 
particular GSE. The induced resistance to cisplatin and reduction in the steady-state level 
of p53 protein caused by expression of the antisense p53 GSEs further confirms the 
association between loss of p53 function and cisplatin resistance in these human ovarian 
tumour cells (Brown et a l , 1993; Eliopoulos et a l , 1995).
The sense-oriented GSEs were not anticipated to modulate p53 protein synthesis 
but work by encoding dominant negative mutant peptides (Roninson et a l , 1995). These 
peptides may inactivate p53 function in a variety of ways, perhaps by interference with 
modular activities such as sequence-specific DNA binding or oligomerisation 
(Herskowitz, 1987). GSEl-carrying cells contained increased levels of p53 protein (1.5 
fold) compared to vector alone controls (Table 4). This may reflect stabilisation of 
endogenous p53 protein through interaction with the GSE1-derived peptide.
It was important to address what effect introduction of GSE1 into A2780 cells 
had on DNA damage induced G1 arrest and apoptosis. Radiation induced G1 arrest is 
dependent on wild-type p53 function in A2780 cells (Mcflwrath et a l , 1994). Vector 
alone A2780 transfectants displayed a functional G1 arrest after irradiation, as measured 
by inhibition of DNA synthesis (Figure 23A and Table 5). This inhibition was partially 
abrogated in a pool of GSE1 transfectants, suggesting that the p53 protein was
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inactivated in these cells, albeit marginally. Quantitation of cisplatin induced apoptosis 
was achieved using fluorescent (FTTC) end-labelling of DNA strand breaks and flow 
cytometric detection as previously described (section 3.2). After cisplatin treatment, a 2.3 
fold reduction was observed in the fraction of FTTC-positive GSE1 transfectants 
compared to vector alone controls (Figure 23B and Table 5). This demonstrates that 
GSEl-canying cells engaged apoptosis less readily than vector alone cells in response to 
cisplatin. Overall, these results suggest that p53 function is revoked by the sense-oriented 
GSE. No dissociation of cell cycle arrest and apoptosis activities was observed with this 
GSE.







VECTOR 45 20 45 (3) 1 17 16 (5)
GSE1 44 27 61 (1) 1 8 7 (2)
Principles of analysis, treatments and timepoints as outlined in Figure 23. C refers to untreated control 
samples. Each value represents the mean of four independent determinations with at least 15,000 events 
counted in each sample. The figures in parenthesis refer to the SEM. a. The percentage of total cells 
which were synthesising DNA and, therefore, incorporating BrdUrd. IR§ refers to radiation induced 
inhibition of DNA synthesis and was calculated using the number of treated cells in S phase expressed as 
a percentage of control samples, b. The percentage of total cells which were undergoing apoptosis. Cis^ 
refers to cisplatin induced apoptosis and was calculated after deduction of the basal apoptosis level as 
determined in untreated controls.
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Figure 23. DNA damage induced responses in A2780 GSE1 transfectants.
(A) Radiation induced cell cycle arrests. Cell cycle analysis was accomplished by flow cytometric 
measurement of BrdUrd incorporation during a 4h pulse and PI staining as previously described 
(section 3.2). Cells were treated with 2Gy y-radiation and analysed 24h later.
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(B) Cisplatin induced apoptosis. Flow cytometric analysis of DNA strand breaks as previously 
described (section 3.2). Increase in FITC represents fluorescent labelling of strand breaks. DNA was 
stained with PI. Cells were treated with 40iiM cisplatin for lh and analysed 72h later.
4.5 BIOLOGICAL ACTIVITY OF GSE1-ENCODED PEPTIDE
The results presented in the previous two sections indicate that introduction of GSE1 
into A2780 cells conferred cisplatin resistance by abrogation of the endogenous p53- 
mediated DNA damage response pathway. To determine whether this effect was due to 
inhibition by the predicted p53-derived peptide encoded by GSE1, a peptide (PEP1-F) 
was synthesized which represented the entire 17 amino acid sequence anticipated by 
sequence analysis (which includes 3 amino acids at both termini derived from the adaptor 
sequences). A control peptide (PEP1-R), which has the same amino acid composition but 
in reverse order, was also synthesized. The control peptide did not show any significant 
homology to any presently known peptide sequences in the SwissPROT database.
Although small peptide molecules are commonly highly flexible, some basic structural 
information can be extrapolated from the primary structure. The basic structural 
characteristics of PEP1-F are displayed in Figure 24. The presence of two adjacent 
proline residues (Pro4 and Pro5) may have important structural implications in providing 
a high degree of constraint to the peptide in this region (Figure 24A). In fact, there is a 
strong possibility of a turn in the peptide between Pro5 and Gly6 (Figure 24B). Another 
turn may exist between Prol3 and Asnl4. The central portion of the peptide appears to 
be quite hydrophilic and flexible (Figure 24C and D) and is likely to be on the surface of 
the molecule (Figure 24E). More detailed information on peptide structure would require 
NMR and circular dichromism studies.
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Figure 24. Structural characteristics of PEP1-F.
The PEPTIDESTRUCTURE and PEPPLOT programs within the GCG package were used to determine 
various structural characteristics of PEP1-F. The peptide was too short to reasonably predict any 
secondary structures apart from turns. Both turns and quantitative site- and residue-specific attributes 
such as hydrophilicity, surface probability and flexibilty are shown as continuous curves. An increase 
above indicated thresholds suggests a greater probability of a section of peptide adopting a particular 
structure or attribute. (A) Primary structure of PEP1-F. Residues are designated by 3 letter codes and 
numbered 1-17 starting from the N-terminus. Amino acids shown in blue are derived from p53. (B) 
Regions of the peptide molecule typically found in turns. (C) Hydrophilicity. (D) Flexibility. (E) Surface 
probability.
Peptides may be introduced into cells by a variety of methods including cationic 
liposome-mediated transfer or conjugation to a carrier molecule (e.g. Penetratin: Derossi 
et a l, 1994). Cationic lipids (e.g. DOTAP: Chen et a l, 1993) require interaction with 
negatively charged molecules in order to form liposomes. The presence of two acidic 
amino acids (Asp2 and Glul7) within PEP1-F suggested that such lipids could be 
effective at introducing the peptide into A2780 cells. PEP1-F induced resistance to 
cisplatin when introduced into A2780 cells by liposome-mediated transfer (Figure 25A). 
The control peptide did not modulate the sensitivity of A2780 cells to drug treatment. 
The effect on cisplatin resistance mediated by PEP1-F was dependent upon dose and 
time of administration. IC50 values from individual experiments (MTT cell viability assay 
used) were compared using a paired Student's t-test. A significant effect on resistance 
(RF=2.9; p value < 0.05) was demonstrated only when lOpM peptide was added 24h 
after cisplatin exposure (Figure 25A, right graph). Little or no effect was observed with 
lpM nor when 10p,M peptide was added at the same time as cisplatin treatment (Figure 
25A, top and left graph, respectively). Maximal accumulation of p53 protein and 
transcription of CIP1 mRNA in A2780 cells occurs 24h after treatment with cisplatin 
(sections 3.3 and 3.4). This may be the critical time point for inhibition of p53 function 
with PEP1-F.
Wild-type p53 protein has a cryptic sequence-specific DNA binding function 
which can be activated in vitro by a variety of modifications including either deletion or 
phosphorylation of the C-terminal negative regulatory domain (Hupp et a l, 1992, Hupp 
et a l, 1995; Hansen et a l, 1996). PEP1-F inhibited binding of Baculovirus-expressed
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human p53 protein to its consensus site in a dose-dependent manner (Figure 25B, top 
panel). Maximal inhibition was observed with a 10 fold excess of peptide compared to 
p53 protein. The control peptide appeared to stimulate DNA binding at high 
concentrations. Neither peptide affected the ability of a mutant p53 protein (A30), which 
has the last 30 C-terminal amino acids deleted (Hupp et al. , 1992), to bind specifically to 
its consensus site (Figure 25B, bottom panel). Small basic peptides have been shown to 
activate the latent sequence-specific DNA binding function of p53 (Hupp et a l , 1995). It 
is possible that the stimulatory activity of the control peptide at high concentrations may 
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Figure 25. Biological activity of PEPl-F .
(A) Cisplatin resistance o f A 2780 cells transfected v\ itli synthetic peptides was determ ined by MTT  
analysis. Peptides were added to a final concentration o f  either 1 or lOpM using liposom e-m ediated  
transfer at the same time as cisplatin treatment or 24h later. Cells were exposed to peptides for 24h 
before washing. PEP1-R. solid line and open circles: PEPl-F . broken line and closed circles. Cell 
viability was determined relative to optical density readings at 570nm . Curve fitting was achieved using 
Sigm aPlot 1.02 (Jandel Corporation). Each point represents the mean o f four independent 
determinations with the error bars referring to the SEM . Fold resistance measurem ents <RF) were 
calculated using IC^q values obtained from at least three experim ents. The figures in parenthesis refer 
to the SEM. All calculations were made relative to control peptide A 2780 transfectants. A paired 
Student's t-test was used to compare IC^q values from individual experim ents. (B ) Gel mobility shift 
assay show ing activated p53-D N A  com plexes. All lanes contained excess radiolabelled D NA  probe and 
p53 protein - top (wild-type) and bottom (A30 mutant) panel. Synthetic peptides (P E P l-F  and -R) were 
added to final concentrations indicated.
4.6 SUMMARY
Induced resistance of A2780 cells to cisplatin was used as the selection strategy to isolate 
GSEs from retroviral libraries expressing random fragments of human or murine TP53 
cDNA. Six GSEs were identified, encoding either dominant negative mutant peptides or 
antisense RNA molecules which corresponded to various regions within the TP53 gene. 
Both types of GSE induced cisplatin resistance when introduced individually into A2780 
cells. Expression of antisense GSEs led to decreased intracellular levels of p53 protein. 
One sense GSE induced loss of p53-mediated activities such as DNA damage induced 
G1 arrest and apoptosis. A synthetic peptide, representing the predicted amino acid 
sequence of this GSE, conferred resistance to cisplatin whe introduced into A2780 cells 
by liposome-mediated transfer and inhibited the sequence-specific DNA binding activity 
of p53 protein in vitro.
A possible limitation of this work was that the level of GSE expression remained 
undetermined. RT-PCR would be ineffective at measuring the extent of antisense GSE 
expression as two transcripts are produced from the proviral element (Figure 4). 
Therefore, the only alternative would be Northern blot analysis using the antisense GSE 
DNA as a probe. Determination of the expression level of the sense-orientated elements 
would require the generation of antibodies against the predicted peptides, followed by 
Western blot analysis. An approach to alleviate clonal variability of GSE expression is 
discussed in the next chapter. Finally, it must also be realised that less than 25% of the 
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CELLS
5.1 CELL CYCLE ARRESTS, APOPTOSIS AND p53
Chapter 3 examined the ability of two DNA damaging agents, ionising radiation and 
cisplatin, to induce cell cycle arrests and apoptosis in the human ovarian A2780 
carcinoma cell line and a series of cisplatin resistant derivatives. The primary advantage 
of this model system is that an isogenic group of cell lines was used (i.e. resistant lines 
generated from one sensitive precursor), thus obviating the problems associated with cell 
type variability. A variety of cell cycle perturbations induced by cisplatin have been 
reported including a decrease in the Gl/S transition, delayed transit through S-phase and 
a G2 arrest (Demarcq et a l, 1992; Brown et al, 1993; Ormerod et a l, 1994 and 
references therein). After cisplatin treatment of A2780 cells, it was observed that fewer 
cells entered S-phase from G1 which is consistent with a block at the Gl/S boundary 
(section 3.2, Brown et a l, 1993). Furthermore, there was an increase in the number of 
late S-phase cells which indicated a slow-down in progression through this cell cycle 
stage.
Some studies have suggested that S-phase delay is the most important cytokinetic 
event after cisplatin treatment (Jackel and Kopf-Maier, 1991; Vaisman, Varchenko and 
Chaney, unpublished observations). However, rigorous examination of S-phase delay in 
the A2780 cell line and its cisplatin resistant derivatives was not carried out. The 
observation of a cisplatin induced G1 arrest in A2780 cells contrasts with the work of 
other investigators using human lung A549 carcinoma cells (wild-type p53 status) and 
murine L1210 leukaemic cells (unknown p53 status) which had suggested that cisplatin
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does not induce a G1 arrest in mammalian cells (Demarcq et al., 1992; Ormerod et al.,
1994). Such differences may be due to cell type variability in the p53 response to DNA 
damage (subsection 1.1.9).
Loss of p53 function in A2780 cells by introduction of a dominant negative p53 
mutant (codon 143, Val to Ala) conferred resistance to multiple agents, including 
ionising radiation and cisplatin (Mcllwrath et al., 1994; Vasey et al., in press). Indeed, 
both G1 arrest and apoptosis induced by either ionising radiation or cisplatin are 
dependent upon an intact p53-mediated DNA damage response pathway in this particular 
cell line (Mcllwrath et al., 1994; Mcllwrath, Vasey and Brown, personal 
communication). A cisplatin resistant A2780 derivative, A2780/CP70, displayed a 
reduced ability to undergo G1 arrest and apoptosis after exposure to either ionising 
radiation or cisplatin (section 3.2). Furthermore, the A2780/CP70 cell line showed loss 
of p53 transcriptional activity, both on a constitutive basis and in response to DNA 
damage (section 3.4). Similar observations were noted in a series of recently isolated 
cisplatin resistant A2780 derivatives (Table 1; Anthoney et a l, 1996). Although the 
above experiments utilised “indirect” measures of p53 function, taken together the results 
indicate that the p53-mediated DNA damage response pathway is defective in these 
cisplatin resistant lines. The proposed mechanism of p53 dysfunction in these resistant 
lines is discussed in the next section.
Failure to undergo apoptosis in response to DNA damage is presumed to be the 
crucial event leading to acquired cisplatin resistance in these resistant lines. Cisplatin has 
been demonstrated to induce apoptosis in a number of cell systems (Evans and Dive et
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al., 1993; Gorczyca et al., 1993). Thymocytes from TP53 null mice are resistant to the 
induction of apoptosis by cisplatin, as are dominant negative p53 mutant (codon 143, Val 
to Ala) transfectants of A2780 cells (Vasey et a l, in press). Recent data has shown 
overexpression of bcl-2 protein in A2780/CP70 cells (Eliopoulis et al., 1995). In 
addition, introduction of a BCL-2 gene into A2780 cells resulted in protection from 
cisplatin induced apoptosis (Eliopoulis et al., 1995). These results are comparable with 
another study which demonstrated an association between the development of cisplatin 
resistance, mutation of the TP53 gene and reduced BAX expression in an alternative 
ovarian carcinoma cell line model system (Perego et a l, 1996). Therefore, p53- 
dependent regulation of downstream effectors of apoptosis such as BCL-2 and BAX may 
be important in determining the response of these cells to cisplatin.
It has been suggested that the G2 arrest induced by cisplatin is a prerequisite for 
cell death and that essential events occur during G2 which are necessary for death to 
occur by apoptosis (Eastman, 1990). The A2780/CP70 line displayed an abrogated G2 
arrest in response to cisplatin but not ionising radiation (section 3.2). Indeed, the other 
cisplatin resistant A2780 derivatives have shown a reduced cisplatin induced G2 arrest 
also (Brown et al., personal communication). Overall, the above results suggest that 
these resistant cells lose, at least partially, the ability to undergo cisplatin induced 
apoptosis through both p53-dependent and -independent pathways. A possible effector 
of p53-independent cisplatin induced apoptosis is the mammalian homologoue of the C. 
elegans cell death gene CED-3, known as ICE (Kondo et al., 1995).
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Cisplatin has been shown to induce apoptosis in proliferating, but not quiescent, 
thymocytes (Evans et al., 1994). In contrast, other DNA damaging agents such as 
ionising radiation and etoposide appear to induce apoptosis independent of proliferation 
status. It has been proposed that DNA replication is necessary for conversion of cisplatin 
adducts into lesions capable of inducing apoptosis (Brown et al., 1995). Consistent with 
this hypothesis was the observation of slower kinetics of p53 protein accumulation and 
CIP1 mRNA induction by cisplatin compared to that for ionising radiation (sections 3.3 
and 3.4). The slower cisplatin induced responses are similar to those previously reported 
for UV damage induced p53 reponses (Khanna and Lavin, 1993; Lu and Lane, 1993). 
UV treatment of cells modifies DNA by causing thymine dimer formation but may also 
cause DNA strand breaks during NER or replication of the damaged DNA template 
(Nelson and Kastan, 1994). Therefore, both cisplatin and UV may share some 
components of the p53-mediated DNA damage response pathway not utilised by other 
agents.
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5.2 MECHANISM of p53 DYSFUNCTION IN CISPLATIN RESISTANT CELLS
The cisplatin resistant A2780/CP70 cells have elevated levels of p53 protein, which is 
associated with dysfunctional p53-mediated reponses to DNA damage, yet they have 
wild-type TP53 mRNA sequence (Brown et al. , 1993). The p53 protein in these cells 
does not appear to be in a conformation often adopted by certain mutant forms of p53, as 
defined by conformation specific antibodies (Brown et a l, 1993). DNA damage was still 
able to induce increased p53 accumulation in these resistant cells, albeit with different 
kinetics to the parental line (section 3.3). In this respect, levels of p53 protein were 
sustained in A2780/CP70 cells as late as 96h after DNA damage. There is no evidence 
for overexpression of mdm2 protein in these cells, indeed mRNA levels of MDM2 were 
decreased along with other p53-responsive genes such as CIP1 (section 3.4). This 
suggests that the defect in the p53-mediated DNA damage response pathway is not 
downstream of p53.
However, no apparent differences were observed between A2780 and 
A2780/CP70 cells regarding the expression of p53 protein through the cell cycle (section 
3.3). It must be considered that cell synchronisation may have revealed subtle changes in 
the cell cycle related expression of p53 protein in these cells. 2D-PAGE revealed no 
gross differences in the pattern of p53 protein isoforms between A2780 and A2780/CP70 
cells (although again minor alterations may be present which were not resolved by this 
system). The p53 status of the remaining cisplatin resistant lines (A2780/MCP1-9) is 
unknown at present. Therefore, it is unclear whether these resistant lines have the same 
type of p53 dysfunction as that observed in A2780/CP70 cells.
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Evidence is accumulating to suggest that cisplatin resistant A2780 derivatives 
also frequently acquire a microsatellite instability (RER+) or mutator phenotype (Table 1; 
Anthoney et a l, 1996), which is associated with defective mismatch repair (MMR) and 
loss of hMLHl mRNA and protein expression (Drummond et al., 1996; Brown et al., 
personal communication). It is possible that the loss of p53 function in these cisplatin 
resistant cells is caused directly by the mutator phenotype. Direct sequestration of p53 
may occur due to binding to DNA damage which may be tolerated in the resistant RER+ 
lines. In support of this hypothesis, it has recently been demonstrated that p53 is capable 
of binding to insertion/deletion mismatches (Lee et a l, 1995). Furthermore, the 
observation of increased nuclear p53 accumulation in some of the RER+ lines would be 
consistent with the concept of p53 sequestration (section 3.3).
Alternatively, it is possible that certain MMR proteins are necessary for coupling 
of DNA damage to the p53-mediated DNA damage response pathway. In fact, the 
MutSa component of the MMR complex can specifically recognise the cisplatin 1,2 
intrastrand crosslink (Duckett et a l, 1996). Moreover, dumbbell substrates containing 
single mismatched bases have been shown to induce a p53-dependent G1 arrest (Wahl et 
al., personal communication). A connection has also been demonstrated between the 
MMR system and the G2 arrest induced by certain alkylating agents (Hawn et al., 1995). 
It is proposed that any agent that induces DNA mispairs (or signals to the MMR system) 
will cause a G2 arrest in MMR-proficient cells but not in MMR-deficient cells. 
Therefore, the loss of the cisplatin induced G2 arrest in A2780/CP70 cells (and possibly 
the other resistant lines also) may be due to the MMR defect (section 3.2). In summary,
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defective MMR in these cisplatin resistant cells may lead to tolerance of DNA damage 
and reduced ability to engage both p53-dependent and -independent apoptotic pathways.
5.3 CLINICAL RELEVANCE OF p53 DYSFUNCTION
p53 appears to be an important determinant of response to cancer therapy in a wide 
spectrum of tumour types (Lowe, 1995). A large number of studies have associated 
TP53 mutations within the same tumour type with poor patient prognosis, hence, a 
reduced probability that therapeutic intervention will be effective (Chang et al. , 1995b 
and references therein). Patients with acute lymphoblastic leukaemia displayed 
substantially reduced survival and response to reinduction therapy on relapsing with 
TP53 mutations (Diccianni et al., 1994). Similarly, in cases where TP53 mutations 
occurred in low-grade bladder tumours, patients showed a high probability of relapse 
after surgery and adjuvant therapy (Yoshimura et al., 1995). A large study incorporating 
316 consecutively presented breast cancers indicated that TP53 mutations were 
associated with worse prognosis and reduced effectiveness of adjuvant therapy (Bergh et 
al., 1995). Interestingly, mutations of TP53 are not associated with chemoresistance in 
Burkitt’s lymphoma (Preudhomme et al. , 1995), but Burkitt’s lymphoma lines with TP53 
mutations are more resistant to anticancer agents when treated in culture. This apparent 
discrepancy may be explained by the level of residual p53 activity in tumours compared 
with cell lines: Burkitt’s lymphoma with TP53 mutations typically retain a normal TP53 
allele, whereas the cell lines do not (O’ Connor et al., 1993; Fan et a l , 1994). Therefore,
130
careful consideration must be given to results from in vitro experiments before 
extrapolation to the in vivo clinical situation.
The observation that defective p53 function correlates with cisplatin resistance in 
the A2780 cell line model system may have important clinical relevance (Chapter 3). 
Many cisplatin sensitive tumour types express wild-type p53 (Peng et al., 1993). Some 
recent reports have suggested a clinical correlation between the presence of wild-type 
p53 and sensitivity to platinum based chemotherapy in ovarian cancer (Al-Azraqi et al., 
1994; Righetti et al., 1996). In addition, elevated levels of p53 protein, as detected by 
immunohistochemistry, have been correlated with resistance to chemotherapy in ovarian 
cancer, although this elevated p53 protein is again not explained in all cases by TP53 
mutations (Righetti et al., 1996). Thus, the phenotype of the A2780/CP70 cells 
(increased accumulation of p53 protein without mutation of the gene) may be relevant to 
clinically resistant ovarian tumours. Specifically, the absence of TP53 mutation in cells 
does not ensure that the p53-mediated DNA damage response pathway is intact 
(Vogelstein and Kinzler, 1992). This problem clearly complicates studies investigating 
the association between TP53 mutation and drug resistance.
If p53 function is an important determinant of sensitivity to DNA damaging 
agents in certain tumour types, several means of overcoming or modulating resistance 
can be envisaged. The most apparent is the utilisation of drugs which act in a p53- 
independent manner or are more effective in cells with defective p53. Dominant negative 
p53 mutant (codon 143, Val to Ala) transfectants of A2780 cells, while resistant to 
cisplatin, retain sensitivity to a number of agents including taxol and camptothecin
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(Vasey et a l, in press). Intriguingly, recent evidence has demonstrated that loss of p53 
function in human and murine fibroblasts confers increased sensitivity to taxol (Wahl et 
al. , 1996). If resistance is due to loss of p53 function then approaches which restore p53 
function may increase drug sensitivity. Combination therapy using a p53-expressing 
adenovirus and cisplatin restored chemosensitivity to transplanted tumours harboring p53 
mutations, producing substantial and sustained tumour regression (Fujiwara et al. , 1994). 
Interestingly, a study using retrovirus-mediated transfer of wild-type p53 into tumours of 
patients with lung cancer has recently been undertaken (Roth et a l , 1996). Such gene 
replacement therapies are predicted to work by inducing tumour cell death through either 
direct killing or bystander effects (Rosenfeld and Curiel, 1996). However, strategies such 
as these are limited by the method of gene transfer used and the expression level of the 
therapeutic transgene required. In addition, any adverse effects of the transgene on 
normal cells must be minimised.
Strategies are also being developed which target cells with mutant or defective 
p53. For example, the altered protein encoded by mutant TP53 alleles could serve as an 
antigen to direct an immune response against the tumour (Wiedenfeld et al., 1994). 
Another approach is to use modified adenoviruses to selectively destroy p53-deficient 
cells. An attenuated adenovirus deleted in the ElB gene has been shown to replicate and 
be oncolytic predominantly in cells with defective p53 (McCormick et al. , unpublished 
observations). It is hypothesised that this may provide a means of targeting p53 defective 
tumours without affecting normal cells, and could effectively lyse cells which acquire 
resistance due to defective p53. A Phase I trial using the E1B deleted-adenovirus for
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treatment of head and neck tumours is currently taking place within the CRC Department 
of Medical Oncology, Glasgow.
Several investigators have suggested the possibility of modulating p53 function 
using small peptides or peptidomimetic drugs (Anderson and Tegtmeyer, 1995; Hupp et 
a l, 1995). In particular, the feasibility of using small molecule approaches for restoring 
p53 function was based upon the observation that short basic peptides derived from the 
C-terminus of p53 activated sequence-specific DNA binding to its consensus site (Hupp 
et a l , 1995). Reactivation of mutant p53 using such molecules may lead directly to 
suppression of tumour growth, but could also modulate the sensitivity of the tumour cells 
to DNA damage. Finally, making certain cells more resistant to the adverse effects of 
chemotherapy may prove useful in the effective treatment of human cancer. For example, 
the generation of drug resistant bone marrow may facilitate the development of 
aggressive chemotherapeutic regimens that might otherwise be lethal due to marrow 
toxicity (Baneijee et a l , 1994; Flasshove et a l , 1995).
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5.4 CISPLATIN RESISTANCE p53 GSES
Loss of p53 function by introduction of a dominant negative p53 mutant (codon 143, Val 
to Ala) into the A2780 cell line has been shown to induce resistance to cisplatin (Vasey 
et al. , in press). This phenomenon has been utilised during the selection of random TP53 
cDNA fragments which confer cisplatin resistance in A2780 cells (Chapter 4). A number 
of GSEs have been isolated from both human and murine TP53 cDNA which are in 
either sense- or antisense-orientation (section 4.3). Each type of GSE induced cisplatin 
resistance when introduced individually into A2780 cells (section 4.3). Levels of 
resistance were comparable with those previously observed when a dominant negative 
p53 mutant (codon 143, Val to Ala) is expressed in the same cell line (Vasey et a l in 
press). It is noteworthy that GSEs derived from murine TP53 cDNA acted in a human 
cellular context. This may reflect the high degree of evolutionary conservation found in 
the TP53 gene and/or the potent biological activity of the isolated GSEs (Gudkov et al., 
1993).
All of the antisense-oriented GSEs were derived from the central portion of the 
TP53 gene (spanning nucleotides 361-680) and this seemingly nonrandom distribution of 
biological active antisense elements has been previously observed by others (Gudkov et 
al., 1993). Antisense oligonucleotides which target p53 expression are currently being 
used in clinical trials (Bishop et al., 1996). Such agents are directed against a variety of 
regions within the TP53 gene, including exon 10 and the translation initiaton codon 
(Bayever et a l, 1994; Bi et a l, 1994). However, some concern has been expressed that
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the phenotypic effect of some antisense oligonucleotides may be unrelated to the gene 
they have been designed to target (Barton and Lemoine, 1995). Expression of GSEs 
encoding antisense RNA reduced the intracellular level' of p53 protein in A2780 cells 
confirming their inhibitory activity on p53 expression (section 4.4).
Sense-oriented GSEs are of particular interest as indicators of protein domains 
that are capable of independent functional interactions (Roninson et a l , 1995). It was 
anticipated that GSE1 would encode a 17 amino acid peptide, containing amino acids 
300-310 of the human p53 protein which is localised to a previously uncharacterised 
"linker" region (Table 3 and Figure 21). When expressed in A2780 cells, this GSE 
reduced p53-mediated activities such as cell cycle arrest and apoptosis in response to 
DNA damage (section 4.4). An alternative study has utilised etoposide resistance and 
focus formation as selection strategies for the isolation of various sets of GSEs from rat 
TP53 cDNA (Ossovskaya et a l, 1996). Interestingly, GSE1 overlaps the region where 
the most powerful class of GSEs were observed in this independent study. The isolation 
of GSE1 allows a more precise identification of the region responsible for inhibition of 
p53 activity in this class of GSEs.
Liposome-mediated transfer of a synthetic peptide, comprised of the predicted 
amino acid sequence of GSE1, into A2780 cells conferred resistance to cisplatin (section 
4.5). The effect on cisplatin resistance mediated by the peptide was dependent upon dose 
and, significantly, time of administration. The proposed critical time point (24h after 
cisplatin treatment) coincides with optimum activation of p53 (as defined by maximal p53 
accumulation and transcription of CIP1) in A2780 cells (section 3.3 and 3.4). Therefore,
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a narrow "window of opportunity" may exist for inhibition of p53 function with the 
peptide. Although stability of the peptide is unknown, rapid degradation would 
necessitate prompt interaction of the peptide with its target (presumably activated p53 
protein).
The peptide also inhibited the sequence-specific DNA binding activity of human 
p53 protein in vitro (section 4.5). It is proposed that the peptide achieves its inhibitory 
activity by switching activated wild-type p53 protein to a latent conformation (Figure 26; 
Hupp et a l , 1992). An alternative scenario is that the peptide may interfere with 
oligomerisation of the p53, consequently reducing the number of p53 protein tetramers 
with the ability to bind to its consensus site. In light of the requirement for the C-terminal 
regulatory domain of p53, the peptide may interact with this area in order to mediate its 
inhibitory effects.
Both sense- and antisense-oriented GSEs induced cisplatin resistance in A2780 
cells (which are permissive for p53-dependent apoptosis) through abrogation of the p53- 
mediated DNA damage response pathway by dominant negative interference or reduction 
in p53 protein levels, respectively. These results again indicate a strong association 
between loss of p53 function and cisplatin resistance in these chemosensitive human 
ovarian tumour cells. The efficacy of random fragment selection as a combinatorial 
approach to isolating biologically active p53 GSEs was also demonstrated. In particular, 
this is the first example of GSE selection being used to define the sequence of a 
biologically active synthetic peptide. In conclusion, the work presented in this study 





Figure 26. Proposed mechanism of p53 protein inhibition by PEPl-F.
The p53 protein tetramer exists in either a latent or active state for sequence-specific DNA binding. 
Phosphorylation of the C-terminal regulatory domain (indicated by a rectangle with basic residues 
represented as positive symbols) may convert the latent tetramer to an activated tetramer through a 
concerted transition of subunits. PEPl-F may mediate its inhibitory activity by reversing this 
conformational switch, possibly through interaction with the C-terminal regulatory domain. The 
oligomerisation and linker domains are shown by a black line and the rest of the p53 molecule by a 
cyclinder.
5.5 FUTURE PROSPECTS WITH p53 GSEs
The problem of clonal variability in the GSE experiments may be avoided by using an 
inducible gene expression system. Such an inducible system based on the regulatory 
elements of the TnlO-specified tetracycline-resistance operon of E. coli has been 
described (Gossen and Bujard, 1992). This inducible system may be used to examine the 
phenotypic consequences of switching GSEs on and off in a stringently controlled 
manner. An obvious advantage of using the tetracycline-regulated gene expression 
system is that as the regulatory elements are prokaryotic in origin, control of inducible 
transcriptional activity is not affected by endogenous control elements. Furthermore, and 
potentially of great interest, experimental control of the degree of promoter activity, by 
titration of tetracycline concentration present, may allow examination of possible 
quantitative effects of GSE function.
Further examination of the biological activity of the GSE1-encoded peptide can 
be imagined. The observation that PEPl-F inhibited the sequence-specific DNA binding 
activity of p53 in vitro may have important consequences for the effect of this peptide on 
the ability of p53 to transcriptionally activate certain target genes. The induction of 
cisplatin resistance in A2780 cells after transfer of the peptide may be due to loss of p53- 
mediated activities such as DNA damaged induced G1 arrest and apoptosis. Experiments 
which assess these points may be limited by the mechanism of peptide transfer used. 
Delivery of the peptide may be optimised by coupling to a carrier molecule such as 
Penetratin (Derossi et al. , 1994). It must be considered that the addition of this 16 amino
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acid sequence may have adverse effects on the activity of the PEPl-F peptide. Functional 
mapping of the peptide should also be performed to determine the minimal region 
necessary for activity. Biotin conjugation, subsequent incubation with cell extracts and 
separation using streptavidin beads may allow isolation of proteins which interact with 
the peptide.
Depending upon genetic context, introduction of dominant negative p53 mutants 
can have apparently contradictory effects on cellular cisplatin resistance. For example, 
inactivation of wild-type p53 function in MCF7 cells using a dominant negative p53 
mutant (codon 143, Val to Ala) conferred increased sensitivity to cisplatin (Fan et a l,
1995). Similar sensitisation effects have been observed when the same dominant negative 
p53 mutant is introduced into the A2780/CP70 cell line (Brown et al., 1993), which as 
discussed earlier has abrogated p53 function. Therefore, the PEPl-F peptide may have 
use in reversing cisplatin resistance in these specific genetic backgrounds. Furthermore, 
many tumour cells have inactivated p53 function yet retain wild-type TP53 gene 
sequence (Vogelstein and Kinzler, 1992). Using appropriate selection strategies, it may 
be possible to identify elements from a p53 retroviral expression vector library which can 
restore p53 function in such cells.
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5.6 GENETIC INACTIVATION OF p53 IN MAMMALIAN CELLS
Gene targeting in murine embryonic stem cells has allowed the production of strains of 
mice which carry inactivating mutations in the TP53 gene (Clarke, 1995 and references 
therein). Such TP53 null mice have proved an invaluable resource in describing the 
biological roles of p53. Indeed, studies using either in vivo or cultured cells from TP53 
null mice have indicated functional p53 to be essential for maintaining genomic integrity 
and to have a pivotal role in responding to DNA damage, by either inducing cell cycle 
arrest or apoptosis. Furthermore, the decision between these options appears heavily 
influenced by cell type (Clarke et a l, 1994; Midgely et al. , 1995). The majority of TP53 
null mice survive to birth, but then rapidly develop tumours. However, the strong 
predisposition of TP53 null mice towards thymic lymphomas is a major limitation to 
using such models in the study of human cancer. To counter this, it has been 
demonstrated that the tumour spectrum may be altered by exposure to specific 
carcinogens (Kemp et a l, 1993). Another approach is to interbreed TP53 null mice with 
other mutant strains to alter the genetic background (Morgenbesser et a l , 1994; Clarke 
et a l , 1995). Inactivation of genes in a tissue specific manner may allow the analysis of 
the in vivo consequences of TP53 deficiency within chosen cell lineages.
A number of other studies have directly inactivated p53 within a variety of 
somatic cells of human origin by introduction of dominant negative p53 mutants 
(examples include Mcllwrath et a l, 1994 and Fan et a l, 1995 among others). The 
advantage of these cultured systems is the ease with which they can be manipulated and
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the cellular environment can be controlled. However, as previously discussed it may be 
difficult to relate observations from these contrived cell systems to the in vivo context. 
Recently, dominant negative p53 mutants have been used to separate the cell cycle arrest 
and apoptosis functions of p53 (Friedlander et a l , 1996; Ludwig et a l , 1996; Rowan et 
a l, 1996). The major advantage of the GSE approach used in this thesis is the 
randomness of the selection of functional elements derived from p53. It may be possible 
using this technology to identify further portions or mutants of p53 which can function 
independently from its other biological roles. In conclusion, investigation into the 
biological roles of p53 in both tumour and normal cells and the possible manipulation of 
these may have important ramifications for the effective treatment of human malignancy.
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APPENDIX I
Sequence alignments of isolated p53 GSEs versus human TP53 cDNA. Comparisons 
were made using the FAST A program (contained within the GCG package). The human 
TP53 cDNA clone was obtained from the GenEMBL database (accession code: 
K03199). Coding sequences within this clone started from nucleotide 215. Predicted 
sites o f translation initiation and termination for sense-oriented elements shown in red. 
Anticipated peptide sequences displayed in blue.
Antisense-oriented elements 
GSE2: 100% identity in 102bp overlap
699 689 679 669 659 649
HP 5 3 GCTTGTAGATGGCCATGGCGCGGACGCGGGTGCCGGGCGGGGGTGTGGAATCAACCCACA
I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
GSE2 TGCCGGGCGGGGGTGTGGAATCAACCCACA
10 20 30
639 629 619 609 599 589
HP 5 3 GCTGCACAGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTGAGGGCAGGGGAGTACG
I I I  II  I I I I I I I I I II  I I  I I  I I  I I  I I I  I I I  II I I I I  I I  I I I I I I I  I I I I I I I I I  I I I I I I
GS E 2 GCTGCACAGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTGAGGGCAGGGGAGTACG
40 50 60 70 80 90
579 569 559 549 539 529
HP 5 3 TGCAAGTCACAGACTTGGCTGTCCCAGAATGCAAGAAGCCCAGACGGAAACCGTAGCTGC
l l l l l l l l l l l l
GSE2 TGCAAGTCACAG 
100
GSE3: 78% identity in 121bp overlap
919 909 899 889 879 869
HP 5 3 ATGTAGTTGTAGTGGATGGTGGTACAGTCAGAGCCAACCTCAGGCGGCTCATAGGGCACC
I I I  I I  I N I  I I  M I N I M  I I  II
GSE3 GAGTCAGCCTCGGGTGGCTCATAAGGTTCC
10 20 30
859 849 839 829 819 809
HP 5 3 ACCACACTATGTCGAAAAGTGTTTCTGTCATCCAAATACTCCACACGCAAATTTCCTTCC
M i l l  I I  I I  l l l l l l  I I  M i l l  1111 111111 I 1111111111 I
GSE3 ACCACGCTGTGGGGAAAAGGCTTCCTGTCTTCCAGATACTCGGGATACAAATTTCCTACA 
40 50 60 70 80 90
799 789 779 769 759 749
HP 5 3 ACTCGGATAAGATGCTGAGGAGGGGCCAGACCATCGCTATCTGAGCAGCGCTCATGGTGG
I I  I I I I I I I I I I I I I I M i l l  M i l l  I
GSE3 ACC C GGATAAGAT GC TGGGGAGGAGC CAGGC
100  110  120
G SE4: 100% identity in 69bp overlap
7 9 9  7 8 9  7 7 9  7 6 9  7 5 9  7 4 9  7 4 0
HP 5 3 GATAAGATGCTGAGGAGGGGCCAGACCATCGCTATCTGAGCAGCGCTCATGGTGGGGGCA
GSE4 GC TATC TGAGCAGCGC TCATGGTGGGGGCA 
10  20  30
7 3 9  7 2 9  7 1 9  7 0 9  6 9 9  6 8 9  6 8 0
HP 5 3 GCGCCTCACAACCTCCGTCATGTGCTGTGACTGCTTGTAGATGGCCATGGCGCGGACGCG
I I N I  I I  l l l l l l l l l l l  M i l l  l l l l l l l l l  l l l l l l l
GSE4 GCGCCTCACAACCTCCGTCATGTGCTGTGACTGCTTGTA 
4 0  50  60
GSE5: 79% identity in 53bp overlap






7 7 9 7 6 9 7 5 9 7 4 9 7 3 9 7 2 9
HP 5 3 AGGAGGGGCCAGACCATCGCTATCTGAGCAGCGCTCATGGTGGGGGCAGCGCCTCACAAC
Mi l l  Mi l l  III
GSE5 GGGAGGAGCCAGGCCA 
4 0  50
Sense-oriented elem ents 
GSE1: 100% identity in 33bp overlap
G S E l
M D V P P G S T K R A  
10  20  30
ATGGATGGATGTGCCCCCAGGGAGCACTAAGCGAGCA
HP 5 3 AATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCA
1 0 8 0  1 0 9 0  1 1 0 0  1 1 1 0  1 1 2 0  1 1 3 0
L P N M S E *
40 50
G S E l CTGCCCAACATGAGTGAGTGA
l l l l l l l l l
HP 5 3 CTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATAT
1 1 4 0  1 1 5 0  1 1 6 0  1 1 7 0  1 1 8 0  1 1 9 0
G SE6: 90% identity in 87bp overlap
M G M N X 
10  20




HP 5 3 ACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATC
9 2 0  9 3 0  9 4 0  9 5 0  9 6 0  9 7 0
I  T L E D S X G N L L G R D N F E V R V  
40  50 60  70  80  90
G S E 6
H P53
G S E 6
H P53
ATCACACTGGAAGACTCCNNTGGGAACCTNCTGGGACGGGACAACTTTGAGGTTCGTGTT
I I I  I N I  M i l l  I I I I  I h M  I I  I I  11: 111111111 I I I  l l l l l l l l l  I 1111
ATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCATGTT 
9 8 0  9 9 0  1 0 0 0  1 0 1 0  1 0 2 0  1 0 3 0
C A C P G *
100  110  
TGTGCCTGCCCTGGGTGAGTGAGTGA
11111111 l l l l l l
TGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAG 
1 0 4 0  1 0 5 0  1 0 6 0  1 0 7 0  1 0 8 0  1 0 9 0
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